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Abstract: FOXO transcription factors control proliferation, apoptosis, differentiation and metabolic processes. Loss of 
FOXO function has been identified in several human cancers, and results in increased cellular survival and a 
predisposition to neoplasia, especially in epithelial cancer. FOXO factors are therefore bona fide tumor suppressors, and 
their potential use as therapeutic targets in cancer has been a matter of debate. Importantly, FOXO factors can also 
positively regulate cell survival through the activation of several detoxification genes, complicating its putative 
therapeutic potential. Targeting of FOXO factors has also been proposed for the treatment of metabolic dysfunctions such 
as diabetes mellitus, immunological disorders and neurodegeneration, as well as for the prevention of aging by 
maintaining the hematopoyetic stem cells niche. But again, data has accumulated that cautions against the potential use of 
the FOXO activators in these settings. Therefore, greater understanding of the regulation of FOXO target specificity is 
still needed to boost its use as a therapeutic target. 
The four members of the FOXO family (FOXO1, FOXO3A, FOXO4 and FOXO6) have distinct but overlapping cellular 
functions, although they seem to bind a common set of DNA sites. This fact together with the observation that FOXOs are 
only partially dependent on their DNA binding activity to regulate their target genes highlights the fact that the interaction 
of the FOXOs with other transcription factors is crucial for the FOXO-mediated transcriptional programs. 
In this review, we provide an overview of recent progress in the understanding of the modulation of FOXO activity and 
target specificity by transcription factors and coactivators. 
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INTRODUCTION 
 The forkhead box (FOX) gene family of transcriptional 
regulators is named after de Drosophila melanogaster gene 
fork head (FKH), whose mutation causes defects in head fold 
involution during embryogenesis [1]. Over the past two 
decades, hundreds of FOX genes have been identified and 
classified into subfamilies such as FOXA, FOXP and FOXO. 
All FOX proteins contain a highly conserved ~100-residue 
DNA binding domain. The canonical FKH domain consists 
of three α-helices, three β-sheets and two wing regions that 
flank the β-sheet. Because of the butterfly-like winged 
structure adopted by the DNA-bound FOX proteins, the 
FKH domain has also been termed the winged-helix domain. 
Most FOX proteins bind to DNA as monomers, contacting 
their target sequences via the third α-helix and by flanking 
residues and the two wing regions [2]. 
 The FOXO subfamily of forkhead transcription factors is 
conserved from C. elegans to mammals. C. elegans has one 
FOXO gene (DAF-16) whereas mammals have four FOXO 
family members: FOXO1 (FKHR), FOXO3A (FKHRL1), 
FOXO4 (AFX) and FOXO6. The genes encoding the first 
three proteins, which share high functional and sequence 
similarity, were identified in fusion genes from chromosomal 
translocations occurring in human rhabdomyosarcomas and  
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acute myeloid leukemias. The more distantly related FOXO6 
was identified by degenerate PCR screening [3-6]. 
 FOXO proteins mainly act as potent transcriptional act-
ivators by binding to the conserved consensus core recog-
nition motif TTGTTTAC [7, 8]. The three dimensional struc-
ture of the forkhead domain has been resolved by both X-ray 
crystallography and nuclear magnetic resonance, revealing 
small variations in the secondary structure content and 
topological arrangement among various forkhead domains 
[9-12]. Importantly, X-ray crystallography data show that the 
winged-helix DNA binding domain of FOXA3, and more 
recently FOXO1, has an overall structure similar to the 
globular domain of the linker histones H1 and H5 [13-15]. 
This structural similarity has been shown to endow certain 
forkhead proteins with the ability to bind their sites within 
condensed chromatin, a DNA context from which most other 
transcription factors are excluded. The chromatin binding 
and remodeling functions revealed for forkhead transcription 
factors could be crucial for initiating and dynamically 
modulating active chromatin states, enabling the diverse 
roles of FOXOs as gene regulatory factors [14, 16-18]. Apart 
from the well-folded and highly conserved FKH domain, 
other parts of FOXO proteins are predicted to be intrinsically 
disordered [19]. FOXO1, FOXO3A and FOXO4 have three 
conserved regions (CR1-3) located in these disordered 
regions. The CR3 is an acidic transactivation domain that 
mediates the interaction with the KIX domain of the 
coactivator CREB-binding protein (CBP) [20, 21], which in 
turn interacts with the transactivation domain of many 
transcription factors. The CR3 domain has been shown to 
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partially overlap with the DNA-binding site on the FKH 
domain [11, 22-24]. 
 Despite of having almost identical DNA binding motifs 
and sharing some downstream transcriptional targets [25, 
26], FOXO factors have overlapping but distinct biological 
roles. The functional diversity of FOXO isoforms was 
revealed by targeted gene disruption in mice. FOXO1-null 
embryos die on embryonic day 10.5 as a consequence of 
incomplete vascular development. Moreover, differentiation 
assays showed a markedly different morphological response 
to vascular endothelial grow factor in endothelial cells der-
ived from FOXO1-deficient embryonic stem cells compared 
with wild-type endothelial cells. FOXO1 thus plays a critical 
role in establishing a normal vasculature in the developing 
embryo [27, 28]. Both FOXO3A- and FOXO4-null mice 
survive to adulthood and are grossly indistinguishable  
from their littermate controls, indicating that these factors  
are dispensable for normal vascular development [27, 29]. 
FOXO3A-null female mice display aged-dependent inferti-
lity and abnormal ovarian follicular development [27, 29]. 
FOXO3A deficiency also leads to lymphoproliferation and 
widespread organ inflammation [30]. In contrast to the 
FOXO1- and FOXO3A-deficient mice, FOXO4-null mice 
display no apparent phenotype [27]. The differences in 
FOXO family members function exemplified by the distinct 
phenotype of FOXO1-, FOXO3A- and FOXO4-null mutant 
mice can be attributed at least in part to two important and 
related characteristics of the FOXO factors: their ability to 
activate or repress diverse target genes through the 
cooperative interaction with a various unrelated transcription 
factors, and their capacity to modulate transcriptional 
responses independently of direct DNA-binding [31]. Some 
of the observed differences may also be attributable to the 
differential expression patterns of FOXO factors, although 
FOXO isoforms are expressed in most mammal tissues to 
varying degrees [5, 8, 32]. FOXO1 is abundantly expressed 
in adipose tissues, FOXO3A is abundant in cardiac and 
neuronal tissues, and FOXO4 is highly expressed in skeletal 
and cardiac muscle. FOXO6 is predominantly expressed in 
the brain [33]. 
 FOXO transcription factors promote cell-cycle arrest, 
DNA repair, detoxification of reactive oxygen species, apop-
tosis and autophagy by upregulating specific gene-expres-
sion programs [34-43]. FOXO-dependent cell cycle arrest 
and apoptosis may be critical for the tumor-suppressive 
effect of these transcription factors, and has boosted the 
research on FOXO factors as potential pharmacological 
targets [44]. Expression of active forms of these factors 
reduces tumorigenicity in nude mice [31, 45, 46] and FOXO 
factors have been found to interact with several tumor 
suppressors or oncogenes [47-49]. Moreover, FOXO factors 
are found at chromosomal translocations in human tumors 
 
Fig. (1). The FOXOs are involved in a complex array of regulatory functions both tissue specific and systemic. 
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[3-5]. Because the ability to detoxify ROS and to repair 
damage is correlated with increased organism longevity [50], 
it has been proposed that these particular functions of FOXO 
transcription factors may be relevant to FOXO’s ability to 
control longevity. It has been shown that FOXO trans-
cription factors extend lifespan in invertebrates [51-55] and 
may also prolong mammalian lifespan [56, 57]. FOXO 
proteins also regulate cell differentiation in blood cells [58-
60], vascular endothelial cells [61], smooth and skeletal 
muscle [62] and adipose tissue [63], which may contribute to 
their role in development. Finally, FOXO proteins control 
energy metabolism by promoting gluconeogenesis and by 
enhancing food intake [64-68] (Fig. 1).  
 As FOXO cellular functions are diverse and in some 
cases antagonistic, the activity of these transcription factors 
must be tightly regulated by external stimuli. It is known that 
environmental signals, including insulin, growth factors, nut-
rients, cytokines and oxidative stress, control FOXO levels, 
subcellular localization and transcriptional activity. FOXO 
proteins are also regulated by a variety of post-translational 
modifications, mainly phosphorylation, acetylation, mono- 
and polyubiquitination [69]. 
 The transcriptional regulatory functions of FOXO pro-
teins require nuclear localization. This localization is favored 
in the absence of growth signals and is correlated with an 
attenuation of cell replication. Export from the nucleus is 
regulated by the phosphorylation of FOXO by the serine-
threonine kinase AKT, and also by glucocorticoid-regulated 
kinase (SGK), casein kinase 1 (CK1), and DYRK1A (a 
member of the dual-specificity tyrosine-phosphorylated and 
regulated kinase group), which not only interferes with 
FOXO transcriptional activities, but also promotes its proteo-
lytic degradation. Stress stimuli trigger the relocalization of 
FOXO proteins in the nucleus, even in the presence of 
growth factors. Indeed, in response to oxidative stress, the 
protein kinases MST1 (mammalian Ste20-like Kinase) and 
JNK (c-Jun kinase), trigger the relocalization of FOXO3A 
from the cytoplasm to the nucleus [69].  
 However, one of the main mechanisms by which precise 
regulation of FOXO is achieved is the interaction with bind-
ing protein partners. It has been described that FOXOs can 
associate with a variety of transcription factors, co-activators 
and co-repressors to regulate the expression of diverse target 
genes. These interactions seem to be critical in determining 
the activation of cell type-specific transcriptional programs. 
Furthermore, the activity of these transcription factors is 
differentially controlled in specific tissues in response to 
various types or intensities of external stimuli, and the 
specificity of the regulation is mediated by the interaction 
with specific factors and cofactors. 
1. METABOLISM 
1.1. Physiological Functions 
1.1.1. Gluconeogenesis 
 FOXO1 is a direct transcriptional regulator of the 
gluconeogenic genes glucose-6-phosphatase (G6Pase) and 
phosphoenolpyruvate carboxykinase (pepck) [67, 70-72]. 
Insulin action inhibits liver gluconeogenesis at least in part 
via AKT inactivation of FOXO1 activity. In response to 
insulin, FOXO1 is phosphorylated by AKT and excluded 
from the nucleus [71]. A feed back regulatory loop has also 
been identified with changes in FOXO activity having a 
dose-responsive repressive effect on insulin signaling 
through inhibition of protein phosphatases, which leads to 
altered AKT activation, reduced insulin sensitivity, and 
impaired glucose metabolism [73]. Interest in this pathway 
has been boosted by the finding that induction of the 
PI3K/AKT signaling pathway shortens the lifespan of C. 
elegans, whereas caloric restriction and activation of DAF-
16, the nematode FOXO orthologue, increase longevity [55, 
74-76]. 
Hepatocyte Nuclear Factor 4 (HNF-4) 
 FOXO regulation of HNF-4 is a good an example of how 
FOXOs can work as activators in some situations and as 
repressors in others [31, 68, 77, 78]. HNF-4 is a transcription 
factor expressed mainly in the liver, kidney and intestine that 
binds to a specific DNA element (HNF-4 binding element 
(HBE)) as a homodimer and activates transcription of many 
genes that are involved in glucose, fatty acid, and cholesterol 
metabolism [79-83]. HNF-4 activates the expression of both 
glucokinase (GK) and G6Pase, which catalyze the first and 
last rate-limiting steps in glycolysis and gluconeogenesis, 
respectively. A number of studies have shown that GK is 
inhibited by fasting and activated by feeding, whereas 
G6Pase is activated by fasting and inhibited by feeding. 
Since HNF-4 can only work as a transcriptional activator, it 
was hypothesized that its opposite effects on GK and G6Pase 
gene transcription might arise from interaction with another 
transcription factor. In 2003 it was described that HNF-4 can 
interact with FOXO. The same group recently reported that 
in the absence of insulin, FOXO1 represses the HNF-4 
potentiated expression of GK and simultaneously activates 
the HNF-4-dependent transcription of the G6Pase gene, 
presumably via interaction with CBP and the peroxisome 
proliferator activated receptor (PPAR) γ coactivator 1-α 
(PGC-1α). Both of these HNF-4-dependent effects are 
abrogated by treating cells with insulin, which promotes the 
translocation of FOXO1 to the cytosol [84], resulting in its 
dissociation from HNF-4 [85] and thus shifting the balance 
from gluconeogenesis to glycolysis in the fasted state. 
Although the molecular basis for the opposite outcomes of 
FOXO1 association with HNF-4 is not well understood, it 
must be noted that in the case of HNF-4 the interaction with 
FOXO1 leads to activation when FOXO1 is bound to an 
insulin response sequence (IRS) on the target promoter, but 
it is inhibitory in the absence of a functional IRS [84]. 
 The Peroxisome Proliferator Activated Receptor (PPAR) 
γ Coactivator 1-α (PGC-1α) is a transcriptional coactivator 
identified as an upstream regulator of lipid catabolism, 
mitochondrial number and function (Fig. 2). Consistent with 
its emerging role as a central regulator of energy metabo-
lism, PGC-1α is abundantly expressed in tissues with high 
metabolic rates, such as heart, skeletal muscle, liver, brain 
and brown adipose tissue [86-90]. PGC-1α is a positive 
regulator of fasting-induced liver gluconeogenesis and this 
regulation is mediated through the interaction of PGC-1α 
with FOXO1 and HNF-4. HNF-4 is essential for expression 
of hepatic genes in the absence of exogenous ligands, while 
the action of FOXO1 and PGC-1α is attenuated by insulin 
[67, 91, 92]. Moreover, insulin regulation of PGC-1α action 
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on gluconeogenesis depends on FOXO1 function in hepatic 
cells and mouse liver. FOXO1 acts as a transcriptional 
regulator of PGC-1α expression through direct binding to 
IRSs within the PGC-1α promoter [93]. Interestingly, it has 
been proposed that the formation of the FOXO1/PGC-1α 
complex is positively modulated by N-Acetyl glycosylation 
(O-GlcNAc) of both factors [94]. 
 The central role played by FOXO1 and PGC-1α in the 
control of gluconeogenesis in response to fasting is sup-
ported by several reports showing that PGC-1α is regulated 
by metabolic sensors in a manner that closely resembles the 
regulation of FOXO1. PGC-1α, like FOXO factors, is 
negatively regulated by AKT [95], and activated by AMPK 
[96], and is also a target of the deacetylase SirT1 [97, 98], all 
of which are sensors of the cellular metabolic status. 
However, it has been noted that in conditions where insulin 
signaling is compromised, like in the insulin receptors knock 
out mice, low phosphorylation of FOXO1 by AKT does not 
result in an increased PGC-1α activity [99]. 
1.1.2. Oxidative Stress 
 As mentioned above, PGC-1α regulation of gluconeo-
genesis is mediated by both HNF-4 and FOXO1, and a direct 
interaction between FOXO1 and HNF-4 also mediates this 
regulation. However, so far it is unknown if a ternary PGC-
1α/HNF-4/FOXO1 complex is formed on gluconeogenic 
gene promoters. The notion that such a ternary complex 
could exist is supported by the recent results regarding the 
regulation of selenoprotein P. 
 Selenoprotein P is a plasma protein produced in the liver 
that is responsible for the transport of the essential micro-
nutrient selenium to various extra hepatic tissues [100, 101]. 
Selenoprotein P has been recently identified as a FOXO1 
target gene [102]. It was also found that, like the gluconeo-
genic genes, Selenoprotein P is simultaneously regulated by 
HNF-4, FOXO1 and the coactivator of both PGC-1α, further 
stressing the functional link between these transcriptional 
regulators [103]. 
 Importantly, Selenoprotein P is crucial for the activity of 
several reactive oxygen species (ROS) detoxification en-
zymes such as glutathione peroxidases and thioredoxin 
reductases [104, 105]. It has been known for some time that 
FOXO3A is a positive regulator of the key ROS detoxifica-
tion enzymes Mn superoxide dismutase (MnSOD) and 
catalase [39, 41]. More recently roles for FOXO4 and 
FOXO1 in ROS detoxification have also been suggested [58, 
106, 107]. 
 Our own results [108] and those of others [109, 110] 
identify a key role of PGC-1α in ROS homeostasis in 
various cell types through the coordinated regulation of the 
antioxidant defense system, including the selenoproteins 
thioredoxin reductase 2 (TR2) [108] and glutathione 
peroxidase 1a (GPx1a) [111]. PGC-1α reduces ROS levels 
and prevents mitochondrial dysfunction and apoptotic cell 
death in response to oxidative stress conditions. 
 Further work by our group has shown that PGC-1α and 
FOXO3A cooperate in the transcriptional regulation of the 
mitochondrial oxidative stress protection system. We 
showed that FOXO3A-dependent induction of ROS detoxi-
fication genes requires PGC-1α, since this effect is severely 
curtailed in PGC-1α-deficient endothelial cells. PGC-1α 
action on these genes is equally dependent on the presence of 
FOXO3A. These factors can directly interact, as shown by 
co-immunoprecipitacion and in vitro interaction assays. 
Moreover, both proteins can localize on the same promoter 
regions in co-regulated genes and it was observed that a 
functional FOXO site is required for activation of the sod2 
promoter by PGC-1α. We also demonstrated that FOXO3A 
is a direct transcriptional regulator of PGC-1α, suggesting 
that an auto-regulatory cycle modulates FOXO3A/PGC-1α- 
mediated control of the oxidative stress response. These 
results support the notion that the FOXO3A/PGC-1α 
complex plays a key role in the oxidative stress protection, 
[112]. The concerted action of both PGC-1α and FOXO3A 
on oxidative stress protection is also highlighted by the 
observation that both factors are activated in response to 
 
Fig. (2). The interaction of FOXO1 and FOXO3A with the coactivator PGC-1α illustrates FOXO’s functional plasticity. FOXO1 and PGC-
1α, cooperate to induce gluconeogenesis and heme synthesis in the liver, FOXO3A and PGC-1α co-regulate ROS detoxification genes in the 
vascular endothelium, while PGC-1α prevents FOXO3A induction by of muscle atrophy genes in skeletal muscle. 
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elevated cellular ROS levels [47, 110, 113]. A PGC-1α-
FOXO1 interaction also seems to be important in hepatic 
heme biosynthesis [114]. It has been proposed that PGC-1α 
activation of the ALAS-1 promoter (encoding the rate-
limiting enzyme in hepatic heme biosynthesis) is mediated 
by PGC-1α coactivation of FOXO1, which directly binds to 
this promoter. The PGC-1α-FOXO1-mediated induction of 
the ALAS-1 promoter is repressed by insulin, probably 
through the activation of AKT, which phosphorylates 
FOXO1 disrupting its binding to PGC-1α. 
1.1.3. Glucose Oxidation: Pyruvate Dehydrogenase 
PDK4 
 The pyruvate dehydrogenase complex (PDC) catalyzes 
the conversion of pyruvate to acetyl-CoA in mitochondria 
and is a key regulator of the oxidation of glucose to acetyl-
CoA [115, 116]. Phosphorylation of PDC by the pyruvate 
dehydrogenase kinase 4 (PDK4) inhibits its activity, showing 
that PDK4 is a negative regulator of glucose oxidation. The 
expression of the PDK4 gene is increased by fasting and 
other conditions associated with the switch from the 
utilization of glucose to fatty acids as an energy source 
[117]. Given the central role of PDK4 in regulating PDC 
activity, it is important to understand the molecular mecha-
nisms underlying the regulation of PDK4 expression by 
hormonal and nutritional factors. FOXO1, binding to IRS 
sites, is a positive regulator of PDK4 expression. PDK4 is 
also stimulated by glucocorticoids via two glucocorticoid 
receptor (GR) binding sites. Moreover, PDK4 is also 
regulated by the FOXO1 interacting factors HNF-4 and 
PGC-1α [118-121]. PGC-1α seems to be recruited to the 
promoter through its interaction with estrogen related 
receptor α (ERRα) [122, 123], a nuclear receptor involved in 
fatty acid transport, mitochondrial function and fatty acid 
oxidation [121]. Insulin acts as a key negative regulator of 
PDK4 by several interconnected mechanisms. It inhibits the 
PDK4 induction by both ERRs and ERRα/PGC-1α comp-
lexes in part by promoting the dissociation of FOXO1 and 
PGC-1α from the PDK4 promoter [122]. Furthermore, 
insulin also causes the dissociation of GR from the promoter. 
This result, together with the observation that mutations in 
IRSs sites reduce de ability of GR to stimulate PDK4 expres-
sion [118], suggests that GR and FOXO1 might interact and 
form a regulatory complex with EERα/PGC-1α on the 
PDK4 promoter, although PGC-1α does not appear to be 
necessary for the acute regulation of PDK4 by glucocorti-
coids or insulin [124].  
1.1.4. Muscle Atrophy 
 Recent studies indicate that FOXO transcription factors 
play an important role in promoting muscle atrophy, induced 
in response to muscle denervation or chronic inflammation. 
This effect seems to depend in part on the ability of FOXO 
factors to upregulate genes associated with proteasome-
mediated protein breakdown, including muscle atrophy F-
box (MAFbx)/Atrogin-1 and muscle-specific RING finger 
protein 1 (MuRF-1) [125, 126]. The role of FOXO factors in 
muscle atrophy also likely involves the FOXO-mediated 
induction of apoptosis through the upregulation of cell death 
receptors and various propapoptotic signaling genes, such as 
the Bcl-2-interacting mediator of cell death (Bim) and the 
Bcl-2/adenovirus E1B 19-kDa-interacting protein 3 (BNip3) 
[38, 127-129]. A recent study [130] proposed that FOXO1-
induced muscle atrophy and associated increases in the 
expression of proteolytic and apoptotic genes might occur 
via DNA-binding-dependent and -independent mechanisms 
This notion is supported by experiments done in cells 
expressing a DNA-binding-deficient form of FOXO1, which 
exhibited significant atrophy upon FOXO1 activation but no 
hallmark signs of apoptosis. Gene expression of MuRF-1 
appeared to be independent of DNA binding, whereas 
expression of MAFbx/Atrogin-1 and Bim was significantly 
blunted in cells expressing DNA-binding-deficient FOXO1. 
BNip3 gene expression was significantly elevated in DNA-
binding-deficient mutant cells. 
 When skeletal muscle is deprived of energy or treated 
with glucocorticoids, FOXO1 expression is increased result-
ing in gene activation, while refeeding suppresses FOXO 
transcription [131]. Similarly to the PDK4 promoter, the 
MuRF1 promoter contains a glucocorticoid response element 
(GRE) directly adjacent to an insulin response element 
(IRE), and is positively regulated by the binding of both GR 
and FOXO1 to these elements. Coexpression of GR and 
FOXO1 dramatically and synergistically increases reporter 
gene activity, whereas insulin-like growth factor 1 (IGF-1) 
inhibits dexamethasone-induced MuRF1 expression, sug-
gesting that a GR/FOXO1 complex may also form in this 
promoter context [132]. Other transcription factors that are 
activated in muscle wasting include members of the 
CCAAT/enhancer binding protein (C/EBP) family [133]. 
C/EBPβ and δ are activated in muscle wasting by a 
glucocorticoid-dependent mechanism. Similarly, increased 
skeletal muscle expression and activity of C/EBPβ and δ 
during sepsis in rats is also dependent on GR [134], 
suggesting that GR may mediate C/EBPβ and δ induction. 
Furthermore, dexamethasone treatment increased C/EBPβ 
and δ levels and upregulated C/EBP-dependent gene 
activation in both cultured myotubes and in rats [135, 136]. 
Since FOXO1 is able to induce C/EBPβ expression [137] 
and regulates GR-dependent muscle atrophy, it would be 
interesting to know if FOXO1 cooperates with GR to induce 
C/EBPβ gene expression during atrophy. Interestingly, the 
pro-apoptotic activity of FOXO3A in muscular atrophy 
appears to be inhibited by PGC-1α. PGC-1α overexpression 
has been shown to prevent muscular atrophy associated with 
denervation and fasting, and to reduce the ability of 
FOXO3A to activate Atrogin-1 and MuRF-1. Thus, the rapid 
fall in PGC-1α levels during atrophy might enhance the 
FOXO-dependent loss of muscle mass [138].  
 FOXO3A-mediated upregulation of Atrogin-1 could also 
contribute to the inhibition of cardiac hypertrophy in the 
heart, where Atrogin-1 is reported to interact with and rep-
ress calcineurin (a pro-hypertrophic agent) by targeting it for 
ubiquitin-mediated proteolysis [139]. Interestingly, FOXO1 
and FOXO3A are direct targets of Atrogin-1 dependent 
ubiquitination in the heart [140]. This ubiquitination does not 
target FOXO factors for proteasomal degradation, but rather 
en-hances their transcriptional activity, further supporting an 
important role for the FOXO/Atrogin-1 axis during postnatal 
heart growth. But induction of Atrogin-1 is not the only 
mechanism through which FOXO3A inhibits cardiac 
hypertrophy. It has been reported that overexpression of 
either wild-type or constitutively active FOXO1 or FOXO3A 
reduces calcineurin phosphatase activity and suppresses the 
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expression of the modulatory calcineurin interacting protein 
exon 4 isoform MCIP1.4, a direct target of the calcineurin/ 
nuclear factor of activated T cells (NFAT) cascade, leading 
to inhibition of cardiac hypertrophy in response to pathologic 
stimuli [141]. These findings are particularly interesting 
since they might indicate the existence of a putative FOXO/ 
NFAT regulatory complex. 
1.2. Transcriptional Co-Factors Involved in Post-Trans-
lational Modification: Acetylation and Deacetylation 
(Fig. 3) 
1.2.1. Sirtuins 
1.2.1.1. SirT1 
 Yeast silent information regulator 2 (Sir2), is an NAD+-
dependent histone deacetylase and founding member of the 
family of enzymes known as sirtuins. Sir2 is involved in a 
wide range of cellular processes, including genomic stability, 
aging, ROS detoxification and metabolic sensing [142, 143]. 
In C. elegans, overexpression of Sir2 increases lifespan, 
which requires DAF-16, the yeast homologue of mammalian 
FOXO [144]. This observation has poised the question of 
whether a Sir2 type of activity plays a role in lifespan 
extension also in mammals and whether it is related to 
FOXO regulation. The Sir2 family of genes is a highly 
conserved group of genes with seven human homologues, of 
which SirT1 is the closest homologue of yeast and C. 
elegans Sir2 [145], and hence its activity is the most 
thoroughly investigated. 
 In 2005, it was described that deacetylation of FOXO 
factors by SirT1 overrides the phosphorylation-dependent 
nuclear export induced by growth factors and renders 
FOXOs immobile within the nucleus in hepatocytes. The 
transcription of FOXO-dependent genes is accordingly 
increased, leading to activation of gluconeogenesis and 
increased glucose release from hepatocytes [146]. In the 
same year, it was reported that SirT1 controls hepatic 
glucose output through the positive modulation of PGC-1α 
activity on gluconeogenesis genes [97]. 
 These results, together with previous data showing that 
gluconeogenesis is co-regulated by FOXO1, HNF-4 and 
PGC-1α, suggest the possibility that gluconeogenesis might 
be regulated by a FOXO1/SirT1/PGC-1α/HNF-4 complex. 
This idea is supported by a recent report showing that the 
SirT1 activator resveratrol inhibits GK expression in a 
FOXO1 dependent manner by increasing FOXO1 localiza-
tion in the GK promoter and its interaction with HNF-4. This 
result suggests that SirT1 positively regulates the formation 
of a FOXO1/HNF-4 complex on this promoter [147]. 
 
Fig. (3). The activation of FOXO factors can result in the induction of both apoptosis and survival genes. Interaction of FOXO with 
coregulators and posttranscriptional modification tip the balance. In response to increased oxidative stress, interaction with CBP/p300 
reduces FOXO transcriptional activity on pro-survival genes while it serves as a coactivator on other FOXO target genes. CBP/p300 
acetylates FOXO and triggers its nuclear exclusion and degradation by the proteasome. When the metabolic conditions are adequate, sirtuins 
like SirT1 and SirT2 deacetylate FOXO, facilitating its translocation to the nucleus. SirT1 coactivates FOXO on pro-survival genes while it 
reduces its activity on pro-apoptotic genes. 
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 Regulation of FOXO activity by SirT1 also seems to be 
important for cell-cycle arrest and the upregulation of oxidat-
ive stress protection genes, including p27 and GADD45 [47, 
148]. Moreover, SirT1 simultaneously inhibits FOXO3A 
activity on apoptotic genes such as Bim or Fas-ligand. SirT1 
also stimulates the transcriptional activity of FOXO4 on p27 
and sod2 gene expression [149]. More recently it has been 
shown that moderate overexpression of SirT1 protects the 
heart from paraquat-induced oxidative stress and apoptosis 
via a FOXO1-dependent mechanism [150]. This report also 
showed that overexpression of either SirT1 or constitutively-
active FOXO1 stimulated the expression of the antioxidant 
enzyme catalase, whereas transduction of a dominant nega-
tive form of FOXO1 in cultured cardiac myocytes resulted in 
reduced catalase expression. Interestingly, SirT1 has also 
been shown to directly regulate FOXO3A and FOXO4 
expression. 
 SirT1/FOXO interaction has also been described to 
regulate endothelial angiogenesis. The fundamental role of 
FOXO factors in the control of angiogenesis is well known. 
A recent study has shown that SirT1 regulates endothelial 
angiogenic functions during vascular growth by negatively 
regulating FOXO activity [151]. Vascular endothelial growth 
factor (VEGF) signaling has also been implicated in the 
regulation of FOXO transcriptional activity in endothelial 
cells [152]. A number of VEGF-responsive genes, such as 
VCAM-1, MMP-10, CITED-2 and MnSOD, have been 
identified to be upregulated by the synergistic actions of both 
VEGF and FOXO activities in the endothelium. These genes 
encode for proteins known to be involved in metabolism, cell 
signaling, cell adhesion, stress response, differentiation and 
other cellular functions [152]. These results contradict the 
documented ability of VEGF to induce the phosphorylation 
and nuclear exclusion of FOXO through activation of AKT 
signaling, suggesting that gene regulation by VEGF and 
FOXO is complex and may be modulated by different 
posttranslational modifications and the interaction of FOXO 
with other transcription factors such as the nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB) 
[152].  
1.2.1.2. Other Sirtuins 
 SirT2 and SirT3 have also been proposed to regulate 
FOXO activity. It has been shown that SirT2 is able to de-
acetylate FOXO3A in response to oxidative stress promoting 
its relocalization from the cytoplasm to the nucleus, thereby 
increasing its activity on ROS detoxification genes [153]. 
SirT3 is the only sirtuin whose increased expression has 
been linked to human longevity [154, 155]. Initially des-
cribed as a mitochondrial specific deacetylase, it has been 
recently shown to be a nuclear protein that is translocated to 
the mitochondria upon oxidative stress [156, 157]. It has 
been described that FOXO3A and SirT3 directly interact in 
the mitochondria and that SirT3 activates FOXO3A-
dependent gene expression, probably by increasing the 
binding of FOXO3A to the promoters of its target genes 
[158]. Moreover, it has been reported that SirT3 increases 
the FOXO3A activity on MnSOD and catalase genes in 
cardiomyocytes, thus preventing cardiac hypertrophy [159]. 
FOXO3A was previously shown to prevent cardiac hyper-
trophy by suppressing the calcium/calcineurin dependent 
activation of NFAT [141]. Therefore, NFAT inhibition 
might be indirect and mediated by a reduction in ROS levels. 
1.2.2. CEBP/p300 
 Glucagon induces the activation of cAMP-dependent 
protein kinase (PKA) activation in response to fasting [160]. 
PKA then phosphorylates the cAMP response element 
(CRE)-binding protein (CREB), which in turn interacts with 
the acetylase p300. The acetylation by p300 boosts CREB 
transcriptional activity, resulting in the induction of the key 
gluconeogenesis genes G6Pase and pepck. Glucagon also 
stimulates the gluconeogenic program by triggering the 
dephosphorylation and nuclear translocation of the CREB 
regulated transcription coactivator 2 (CRTC2; also known as 
TORC2) [161]. The gluconeogenic program is also induced 
via the coactivation of CREB by PGC-1α in response to 
fasting [162]. Given the role of FOXO1 in regulating gluco-
neogenesis, these results raise the possibility of an interplay 
between the CREB and the FOXO1 pathways. Recently it 
has been shown that there is a fasting-inducible switch 
between p300 and SirT1 that determines which gluconego-
genesis program is active at a time [163]. This study 
proposes that similarly to what happens in oxidative stress, 
early during fasting there is an activation of p300, which 
induces gluconeogenic gene expression via CRTC2. During 
late fasting, activation of SirT1 leads to CRTC2 downregu-
lation and activation of FOXO1 dependent gluconeogenesis 
program. 
 Both p300 and CBP act as coactivators of FOXO 
proteins, enhancing gene transcription by recruiting basal 
transcriptional machinery or by remodeling chromatin 
structure through intrinsic histone acetyltransferase (HAT) 
activity [164]. It was first shown that DAF-16 recruits CBP 
to activate gene transcription in C. elegans; subsequently the 
physical interactions between human FOXO proteins and 
CBP were identified and mapped [21, 165]. As mentioned 
before, the CR3 acidic transactivation domain of FOXO 
proteins binds directly to the KIX domain of CBP [20, 21]. It 
has been recently reported that the intramolecular interaction 
between the FKH and the CR3 domains of FOXO proteins 
negatively regulates the association of CR3 with KIX [24]. 
However, upon binding to the forkhead response element 
(FRE) DNA, the FKH domain releases the CR3 domain, 
allowing it to interact with the KIX domain of CBP, which 
could enhance its transcriptional activity. p300 and CBP not 
only interact with FOXO factor, they also acetylate them. It 
was initially proposed that p300-mediated acetylation of 
FOXOs increased their transcriptional activity [166, 167]; 
however, a number of recent reports suggest that CBP/p300-
mediated acetylation reduces FOXO transactivation activity 
on a number of key target genes, including those involved in 
oxidative stress protection. In 2003, it was described that 
CBP acetylates FOXO4 at three lysine residues and the 
CBP-induced acetylation of FOXO4 was proposed as a novel 
modification mechanism by which FOXO4 keeps the 
transcriptional activity mitigating in the nucleus [168]. More 
recently, FOXO4 was also found to be acetylated by p300 in 
vivo [169]. This acetylation negatively regulates the trans-
activation activity of FOXO4, although p300 also contri-
butes to FOXO-mediated transactivation by recruiting the 
basal transcriptional complex. Interestingly, deacetylation of 
FOXO4 by SirT1 counteracts p300-mediated downregula-
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tion of FOXO4 activity. Reversible acetylation also modu-
lates the transactivation function of FOXO1. CBP binds and 
acetylates FOXO1 at three lysine residues, attenuating its 
transcriptional activity. This acetylation is counteracted by 
SirT1, which coactivates the transcriptional function of 
FOXO1 via its deacetylase function [170]. Acetylation 
reduces FOXO1 activity by attenuating its ability to bind the 
target DNA sequence and increasing its sensitivity to phos-
phorylation by the phosphatidylinositol 3-kinase (PI3K)/ 
AKT pathway [171, 172]. More recently, it has been re-
ported that the decrease in DNA binding by FOXO1 is a 
result of the CBP/p300-mediated acetylation of the wing 2 
region and it is not nearly as dramatic as the decrease in 
DNA affinity that is caused by MST1-mediated phosphory-
lation. In light of this, it is possible that the CBP/p300-
mediated acetylation of FOXO1 might also change the 
transcriptional activity of FOXO1 by altering essential 
protein-protein interactions [12].  
 A molecular model has recently been proposed in which 
acetylation destabilizes FOXO1 binding to the nucleosome 
binding but not FOXO1-mediated stable nucleosome 
remodeling [174]. FOXO transcription factors stably bind 
target sites on nucleosomes and within linker histone-com-
pacted chromatin arrays, perturbing histone, DNA contacts; 
this activity qualifies the FOXO proteins as ‘‘pioneer fac-
tors” capable of initiating regulatory events in chromatin 
[14]. Stable nucleosome binding, which is essential for 
efficient FOXO chromatin remodeling, is dependent on the 
‘‘forkhead box” DNA binding domain. Recently it has been 
reported stable FOXO1 binding to nucleosome particles and 
efficient chromatin remodeling by acetylated FOXO1 or 
mutant forms containing amino acid substitutions mimicking 
acetylation. The authors propose that, while acetylation 
provides a first, essential step toward removal of FOXO 
factors from cellular chromatin, additional mechanisms, 
possibly in the form of FOXO co-activator/repressor protein 
partners, regulate the inherent capacity of FOXO factors to 
stably bind and remodel nuclear chromatin [173]. This 
scenario would help to explain the apparent paradox that, 
while acetylation curtails FOXO DNA and chromatin 
binding, in some instances acetylation of FOXO factors 
results in enhanced FOXO transcriptional activity [148, 
174]. Interestingly, it has also been recently proposed that 
reactive oxygen species induce the formation of cysteine-
thiol disulfide-dependent complexes of FOXO and p300/ 
CBP. Moreover, modulation of FOXO activity by p300/ 
CBP-mediated acetylation seems to be dependent on the 
formation of this redox-dependent complex [175]. 
2. CELL DIFFERENTIATION AND EM TRANSITION 
2.1. Wnt Signaling 
 Glycogen synthase kinase (GSK) was discovered over 30 
years ago as one of several kinases that phosphorylates and 
inactivates glycogen synthase [176] the final enzyme in 
glycogen biosynthesis. Molecular cloning identified two 
closely related isoforms, GSK3α and GSK3β [177, 178]. 
Some years later it was discovered that insulin inhibits GSK 
activity through AKT phosphorylation [179], while glucagon 
stimulates cAMP activated GSK [180, 181]. It was thus clear 
that GSK activity was inhibited when the cell had high 
glucose levels, and activated when glucose was limiting. 
GSK is also involved in the inhibition of protein synthesis, 
indicating that its role in the response to starvation also 
extends to protein metabolism [182, 183]. Research on 
GSK3 was once again on the front page when the wingless 
(Wnt) signaling pathway was elucidated. The Wnt pathway 
was first identified in Drosophila and Xenopus, where it 
regulates key developmental stages. Wnt inhibits GSK3, 
resulting in the dephosphorylation of β-catenin, which then 
translocates to the nucleus and activates the T cell 
transcription factor (TCF). TCF, originally identified as a T 
cell activating transcription factor [184-186], is required for 
a variety of developmental processes [187]. The importance 
of this pathway in adult organisms was soon apparent from 
studies showing that Wnt signaling is crucial in several types 
of cancer, particularly colon cancer, where colon epithelial 
cells undergo an epithelium to mesenchyme (EM) transition 
[188]. The intriguing position of GSK3 as a tumor 
suppressor and a starvation-induced factor might be related 
to the long standing observation called the Warburg effect, 
which describes how actively proliferating cells switch to 
glycolytic metabolism and suppress all pathways related to 
starvation, β-oxidation, or mitochondrial function, showing a 
fundamental connection between cell proliferation and the 
inactivation of GSK function [189]. 
 In 2005, it was discovered that FOXO3A was activated 
by β-catenin following its activation by oxidative stress [49]. 
That was an unexpected result since β-catenin is a growth-
promoting agent, that seemed to activate a cell arrest/pro-
apoptotic protein. The physiological relevance of this 
apparent paradox was partially elucidated when in 2008 the 
same group reported that FOXO3A interaction with β-
catenin resulted in the inhibition of the β-catenin/TCF) 
complex activity [190] and thus implying that FOXO3A can 
function as a negative regulator of Wnt signaling and as 
inhibitor of the EM transition. Modulation of β-catenin/ 
FOXO3A interaction by cellular stress is also significant in 
relation to cell proliferation since elevated H2O2 levels are 
characteristic of actively proliferating cells and particularly 
of cancer cells. Importantly, it has been shown in C. elegans 
that the β-catenin ortholog BAR-1 is required for the 
oxidative stress-induced expression of the DAF-16 target 
sod-3 and for resistance to oxidative damage [49]. The 
connection between the Wnt/GSK3 pathway and the FOXO 
factors is further supported by the observation that GSK3 
also protects against cardiac hypertrophy, a pathological 
condition characterized by the switching of the cardiomyo-
cytes from oxidative metabolism to glycolysis [191]. 
2.2. Muscle 
2.2.1. Smooth Muscle 
2.2.1.1. Myocardin 
 FOXO proteins are involved in the differentiation of 
several cell types, but they seem to be particularly important 
in the differentiation of vascular endothelial cells and the 
vascular smooth muscle cells (SMCs) [192]. The role of 
FOXO factors in the developing vasculature has been 
highlighted by the observation that FOXO1-deficient mice 
die during embryogenesis and display malformations in 
major vessels of the embryo and yolk sac [27, 28]. In the 
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postnatal vasculature, the role of FOXO factors, has been 
further evidenced by the use of genetically engineered mice 
that allow the inducible ablation of FOXO genes. Accord-
ingly, generalized deletion of all 3 FOXO genes (foxO1, 
foxO3A, and foxO4) results in the appearance of benign 
endothelial cell tumors termed hemangiomas [193]. 
 Endothelial precursors (EPCs) can be differentiated to 
endothelial cells, SMCs and proliferative fibroblasts. SMCs 
and fibroblasts are closely related and can shift phenol-
typically from one cell identity to the other quite easily. This 
shift is regulated by the interaction of the serum response 
factor (SRF) with its coactivator myocardin. FOXO4 
inactivates the SRF/myocardin complex and thus appears to 
act as a brake on the differentiation of EPC into SMCs/ 
fibroblasts [194]. 
 Differentiation of SMCs from embryonic stem cells 
(ESCs) during development is characterized by the appear-
ance of proteins (such as smooth muscle [SM] α-actin and 
SM–myosin heavy chain [MHC]) whose expression is 
restricted to the SMC lineage. However, unlike skeletal and 
cardiac myocytes, which are terminally differentiated, SMCs 
in adult animals readily switch phenotypes in response to 
changes in local environmental cues, such as vascular injury 
or within atherosclerotic lesions. In these situations, SMCs 
decrease expression of SMC-specific contractile proteins and 
acquire a migratory and proliferative phenotype charac-
terized by increased production of extracellular matrix com-
ponents and matrix metalloproteases [195]. After resolution 
of the injury, SMCs resume transcription of SMC-specific 
genes and regain their fully differentiated phenotype. 
 SMC-restricted contractile protein genes contain evolu-
tionarily conserved CArG box DNA sequences within their 
promoters, and these sequences are required for SMC gene 
transcription in vivo. Paradoxically, many other genes 
important for induction of SMC phenotypic switching within 
vascular lesions, including genes important for migration, 
proliferation, and extracellular matrix production, also 
contain CArG boxes within their promoters. CArG boxes 
serve as binding sites for SRF. SRF has the ability to 
simultaneously activate transcription of genes involved in 
opposing cellular processes, such as differentiation and 
proliferation. SRF itself is a weak transcriptional activator, 
and it was thought that SRF must bind to SMC gene pro-
moters and subsequently recruit other muscle-specific 
promyogenic accessory factors with strong transcription 
activation domains (TADs). This idea was validated by the 
discovery of the SRF coactivator myocardin. Myocardin is 
exclusively expressed in SMCs and cardiomyocytes, 
possesses a powerful C-terminal TAD with the capability to 
selectively activate transcription of cardiac and SMC-
specific contractile genes, and physically associates with 
SRF to form a ternary complex on CArG box DNA [196]. 
 SRF cofactors can be divided into two families: the mem-
bers of the ternary complex factor family of Ets domain 
proteins (Elk-1, Sap-1 and Net) and the myocardin-related 
transcription factors (MRTFs) represented by myocardin, 
MRTF-A (MAL, MKL) and MRTF-B [197]. Pathological 
remodeling of the vessel wall involves a switch in SMC 
phenotype, from the differentiated, contractile state to a 
proliferative, “synthetic” state [195]. During this switch, 
cytoplasmic signals activate Ets domain proteins, like Elk-1, 
which associate with SRF on a specific subset of CArG-
boxes flanked by Ets-binding sites [198]. Elk-1 displaces 
myocardin from SRF, resulting in downregulation of a 
subset of smooth muscle genes [199, 200]. Although Elk-1 is 
a coactivator of SRF, it is substantially weaker than 
myocardin, such that the displacement of myocardin from 
SRF by Elk-1 results in an overall decrease in the expression 
of smooth muscle genes.  
 FOXO4 has been proposed to inhibit SMC differentiation 
under proliferating conditions in a DNA-binding independ-
ent manner. FOXO4 is being expressed most abundantly in 
myocyte-containing tissues [8]. FOXO4 interacts with both 
myocardin and SRF and inhibits their transcriptional activity 
while it is bound to the promoter of the target genes, since 
both FOXO4 and myocardin can both be isolated from the 
chromatin of smooth muscle genes. It is well established that 
stimulation of the PI3K/AKT signaling pathway stimulates 
SMC differentiation [201]. PI3K/AKT signaling promotes 
nuclear export of FOXO4, thereby releasing myocardin from 
its inhibitory influence and leading to SMC differentiation 
[202]. Therefore, the association of FOXO4 and myocardin 
appears to play a key role in the modulation of smooth 
muscle growth and differentiation. Several other studies 
support the notion that FOXO factors are antiproliferative in 
SMC. For example, FOXO3A has been shown to inhibit 
neointimal hyperplasia [203], while nuclear exclusion of 
FOXO3A is rapidly induced after carotid balloon injury [204]. 
 This regulatory circuit also seems to be important in the 
differentiation of cardiac muscle, which also requires myo-
cardin. Myocardin levels in the heart increase during cardiac 
hypertrophy [205], and myocardian overexpression induces 
an hypertrophic phenotype [206]; moreover, myocardin is 
inhibited by GSK3β [207], which as mentioned, inhibits 
hypertrophy. Importantly, myocardin expression in the heart 
is positively regulated by FOXO factors, although the 
specific FOXO factors involved have not been identified, 
and it is unknown if this regulation also occurs during SMC 
differentiation [208]. 
2.2.1.2. Sp1 
 Tumor necrosis factor α (TNF-α) is released by macro-
phages and SMCs and it enhances SMC migration and 
promotes the expression of cell adhesion molecules and 
matrix metalloproteinases (MMP). Recent data suggest that 
these effects are partially mediated by FOXO4, since 
FOXO4 genetic deficiency (knockout or knockdown) in 
cultured aortic smooth muscle cells impairs their ability to 
migrate in response to TNF-α, and TNF-α induction of 
MMP9 expression requires FOXO4. Detailed characteriza-
tion of this regulatory circuit showed that it involved the 
formation of a complex between the transcription factor Sp1 
and FOXO4 on the matrix metalloproteinase 9 (MMP9) 
promoter, and that FOXO4 DNA-binding activity was 
dispensable for this effect [209, 210]. 
2.2.2. Skeletal Muscle 
2.2.2.1. Myocardin-Related Factors 
 FOXO1 has been shown to regulate myoblast fusion 
during the differentiation of skeletal muscle, a process in 
which myocardin-related factors play an important role. It 
has been proposed that MRTF-A, like myocardin, can toggle 
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between different protein complexes that redirect its activity 
toward different cellular functions during myogenic differen-
tiation. MRTF-A and -B have been shown to cooperate with 
transforming growth factor β (TGFβ) signaling in this and 
other systems. MRTF-A induces EM transition via induction 
of slug gene in cooperation with Smads [211] and Smad3 has 
been identified as a general modulator of MRTF activity 
during early steps in cancer progression [212]. In proliferat-
ing myoblasts, myogenic differentiation is inhibited by 
transcriptional activation of the Id3 gene by a MRTF-
A/Smad1/4 complex, while FOXO1 is retained in the cyto-
plasm. In contrast, in differentiating myocytes, MRTF-A is 
downregulated, and FOXO1 translocates into the nucleus, 
where it induces the dissociation of the MRTF-A/Smad1/4 
complex to dissociate from the Id3 promoter, thereby 
suppressing the MRTF-A/Smad-dependent Id3 expression. 
FOXO1 thus facilitates the final phase of myocyte different-
tiation and the formation of myotubes [213] by interfering 
with TGFβ signaling. The TGFß downstream effector Smad3 
also binds to myocardin to activate transcription from a 
Smad binding element (SBE) in the promoter of the SM22α 
gene [214, 215].  
2.2.2.2. Notch 
 After ligand-induced cleavage, the intracellular domain 
of the Notch receptor translocates to the nucleus where it 
interacts with the DNA-binding protein Cs1 to generate an 
active transcriptional complex. In mammalian cells, Notch 
activation is generally thought to maintain stem cell potential 
and inhibit differentiation, thereby promoting carcinogenesis 
[216-220]. However, the Notch pathway plays a critical role 
in muscle differentiation during embryogenesis, as evi-
denced by Notch1-/- animals, which show defects in myo-
blast differentiation [221, 222]. Also, active Notch signaling 
or Notch1 receptor gain of function inhibits differentiation of 
C2C12 and 10T/2 myoblasts by suppressing transcription of 
the myogenic determination gene (MyoD) [223, 224]. 
 FOXO transcription factors, as we have shown, regulate 
SMC myogenesis, and they are also implicated in skeletal 
muscle differentiation and maintenance [36, 62, 225-227]. 
MyoD is the predominant myogenic factor in fast (gly-
colytic) fibers while myogenin is the predominant factor in 
slow (β-oxidative) fibers. Targeted knock out of FOXO1 in 
skeletal muscle results in higher numbers of fast/MyoD-
containing myofibers and reduced numbers of slow, Mef2c-
containing fibers [228]. 
 A functional connection between FOXO1 and Noch1 was 
initially appreciated based on the observation that FOXO 
gain-of function and Notch1 activation have similar effects 
on myoblast differentiation, and vascular morphogenesis 
[226]. In C2C12 cells, growth factor withdrawal results in 
myogenic conversion, and ectopic expression of a constitut-
ively active FOXO1 mutant blocked this effect in a DNA-
binding independent manner [227]. Constitutively active 
Notch1 also blocks myoblast differentiation, and FOXO 
siRNA rescued this inhibition, supporting the hypothesis that 
FOXO1 and Notch1 are functionally connected. The same 
study also showed that FOXO1 directly interacts with Cs1 
and this interaction is required for Notch1-mediated induc-
tion of the transcriptional target Hes1. Hes1 has been 
proposed to suppress myoblast differentiation by inhibiting 
MyoD (fast fibers) without affecting Myf5 (slow fibers). The 
authors proposed that FOXO1 works by aiding the dis-
placement of Cs1-associated corepressors (NcoR/Smrt) and 
allowing association of coactivators (Maml1) [228]. These 
findings provide a molecular mechanism by which two dis-
tinct signaling modu-les, PI3K and Notch, can coordinately 
and synergistically regulate muscle differentiation, but they 
also suggest that Notch/FOXO1 might functionally interact 
in other cellular contexts likely to regulate progenitor cell 
maintenance and differentiation, particularly since the 
FOXO factors have been also shown to be necessary for the 
maintenance of hematopoyetic stem cells [58].  
 In some cell types such as keratinocytes, increased Notch 
activity causes exit from the cell cycle and commitment to 
differentiation, whereas down-modulation or loss of Notch1 
function promotes carcinogenesis [229-232]. Recent evi-
dence has established that Notch1 expression in keratino-
cytes is induced by p53 upon UVB exposure [233] and is an 
important p53 target gene in tumor suppression. In this 
cellular context it has been proposed that Notch downregu-
lates FOXO3A expression and therefore prevents the 
induction of apoptotic cell dead upon UVB exposure [234]. 
2.2.2.3. Pax 
 Paired and homeodomain containing proteins (Pax) are 
essential for regulating embryonic organogenesis and 
differentiation in metazoans [235]. The closely related Pax3 
and Pax7 are specifically expressed in the central nervous 
system as well as in skeletal muscle. During embryonic 
myogenesis, Pax3 and Pax7 are expressed exclusively in 
skeletal muscle progenitor cells [236] and play important 
roles in regulating expression of myogenic transcription 
factors [237]. Genetic studies suggest that Pax3 and Pax7 are 
potential upstream regulators of MyoD during both emb-
ryonic and postnatal myogenesis [238, 239]. The importance 
of a possible link between FOXOs and Pax3/7 was initially 
underscored by the finding of a naturally occurring chro-
mosomal translocation between FOXO1 and Pax3/7 that 
results in a Pax3/7-FOXO1 fusion protein in human alveolar 
rhabdomyosarcomas [240]. FOXO3A has been proposed to 
play an important role in skeletal muscle regeneration, since 
FOXO3A deficiency markedly reduces the myotube-forming 
potential of satellite cells, thus revealing a muscle regenera-
tion defect after injury. The underlying molecular mecha-
nism might involve the formation of a FOXO3A/Pax3/7 
transcriptional activating complex on the myod promoter 
[241]. 
2.3. TGF-β  
2.3.1. Smad 
 The TGF-β family members are multifunctional proteins 
that regulate various biological processes, including cell 
growth, differentiation, apoptosis, motility, and extracellular 
matrix production, and thus play essential roles in embryonic 
development and the pathogenesis of various diseases [242]. 
TGF-β transduces signals through heteromeric complexes of 
serine/threonine kinase receptors and intracellular Smad 
proteins [243]. Phosphorylated Smad2 and Smad3 
(Smad2/3) proteins form oligomers, that might or might not 
include Smad4, and translocate to the nucleus, where they 
regulate the transcription of target genes. TGF-β-induced 
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gene expression is frequently modulated by other trans-
cription factors and cofactors that confer target specificity on 
Smad complexes. TGF-β regulates the EM transition, having 
a cytostatic effect on the epithelium and a proliferative effect 
on the mesenchyme. The TGF-β/Smad signaling pathway 
thus functions in cancer development and progression as a 
double-edged sword, acting as a tumor suppressor in early 
tumorigenesis and as a tumor enhancer at later stages. 
TGFβ1 is also a potent profibrogenic factor; for example, in 
the damaged liver it stimulates transdifferentiation and 
proliferation of hepatic stellate cells, increased expression of 
extracellular matrix components, hepatocyte apoptosis and 
liver fibrosis [244]. 
 Several studies have shown that the FOXOs regulate 
TGFβ/Smad signaling both positively and negatively, 
depending on the cellular context. As already mentioned, 
FOXO1 facilitates the final phase of myocyte differentiation 
and the formation of myotubes [213] by forming an inhi-
bitory complex with Smad1/4 and therefore interfering with 
TGFβ signaling. Another example of a negative regulatory 
circuit is the regulation of plasminogen activator inhibitor-1 
(PAI-1) expression. PAI-1 is elevated in pathological con-
ditions associated with hyperinsulinemia, including athero-
sclerosis and hepatic and renal fibrosis [245, 246]. It is 
expressed in many cell types under the control of a variety of 
signals [247], being the most important TGF-β and insulin 
[248, 249]. A recent study has shown that FOXO1 prevents 
insulin-stimulated PAI-1 gene expression, at least in part 
through the inhibition of TGF-β signaling. The authors also 
propose that FOXO1 activity likely depends on its repressive 
interaction with Smad3 on the PAI-1 promoter [250]. 
 Several studies have shown that FOXOs and Smads can 
cooperate in the regulation of metabolism and cell cycle 
control genes. The first clue of such a connection came from 
the finding that TGF-β signaling, like DAF-16, is involved 
in the control of C. elegans metabolism and development 
[251, 252]. Ablation of DAF-2, the C. elegans ortholog of 
the mammalian insulin receptor, exhibited genetic synergy 
with the nematode DAF-7/DAF-3 (TGF-β/Smad) pathway, 
suggesting that DAF-16 can cooperate with nematode Smad 
proteins in regulating the transcription of key metabolic and 
developmental control genes [55]. This work also showed 
that DAF-16 and DAF-3 could form heterodimers that 
repress the expression of genes regulating metabolism and 
development. 
 Mammalian TGF-β delivers cytostatic signals to epi-
thelial, neuronal, and immune cells, and loss of TGF-β 
contributes to tumor development [242]. The TGF-β cyto-
static program involves transcriptional activation of the 
cyclin-dependent kinase inhibitors p21Cip1 and p15Ink4b 
and repression of the growth-promoting transcription factors 
c-myc and Id1-Id3 [253, 254]. In 2004 FOXO proteins were 
identified as key partners of Smad3 and Smad4 in TGFβ-
dependent formation of a p21Cip1 transactivation complex 
[48]. TGF-β induces the binding of Smad2/3 and Smad4 to 
the promoter and the simultaneous removal of c-Myc. TGF-β 
response requires the binding of FOXO factors to a 
functional FOXO binding site (IRE) adjacent to the Smad 
binding site (SBS), and is mediated by the direct interaction  
 
of FOXO factors with Smad3/Smad4. Whole genome 
analysis later showed that a complete set of genes are 
corregulated by FOXO/Smad complexes, and indicated that 
the transcription factor C/EBPβ was likely to be part of the 
regulatory network in a significant number of the corregu-
lated promoters [255-257]. 
2.3.2. C/EBPs 
 C/EBPs are executors of lineage commitment and 
terminal differentiation programs, and have more recently 
emerged as important negative regulators of cell prolifera-
tion. However, C/EBPβ has also been shown to promote 
tumorigenesis in the skin, and progenitor expansion before 
terminal differentiation [258-261]. A subset of FOXO/Smad-
dependent TGFβ gene responses additionally require 
C/EBPβ [256, 257]. For example, in human epithelial cells 
C/EBPβ is essential for TGFβ induction of the cell-cycle 
inhibitor p15INK4b by a FOXO-Smad complex and for 
repression of c-Myc by an E2F4/5-Smad complex. The 
molecular mechanisms underlying C/EBPβ-mediated effects 
have not been completely resolved, but diverse configure-
tions of FOXO and Smad-binding elements in the promoters 
of target genes were identified. Several reports have also 
indicated that TGFβ signaling can also induce Smad3/4-
dependent inhibition of C/EBPβ function [262-264]. 
2.3.3. FOXG1 
 The transcription factor FOXG1 is a determinant of 
forebrain size in vertebrates and has been associated with 
cancer development [2, 265]. FOXG1 functions as a trans-
criptional repressor that protects neuroepithelial progenitor 
cells from cytostatic signals [266]. Its mechanism of action 
seems to involve at least in some cases the inhibition of 
FOXO activity through direct interaction with FOXO 
factors. Interestingly, FOXG1 also inhibits p21Cip induction 
by TGF-β [48], and this is likely to be important in tumor 
progression [267]. The relevance of this regulation in cell 
differentiation in vivo has been further supported by a recent 
work showing that FOXO3A is required for TGF-β-de-
pendent generation of Cajal–Retzius (CR) neurons in 
FOXG1 deficient zones through the induction of p21 [268]. 
2.3.4. Human Kruppel-Like Factor 5 (KLF5) 
 Human Kruppel-like factor 5 (KLF5) is a zinc finger 
transcription factor belonging to the Sp/Kruppel-like family. 
KLF5 is pro-proliferative in some cell types, including 
immortalized but non-tumorigenic epithelial cells, but anti-
proliferative in cancer cells [269-271]. The pro-proliferative 
KLF5 becomes anti-proliferative when TGF-β signaling is 
activated in epithelial cells, playing an essential role in TGF-
β induced p15 expression. KLF5 inhibits p15 transcription in 
the absence of TGF-β but it induces it when TGF-β is 
activated, when KLF5 interacts with Smad on the p15 
promoter. Acetylation of KLF5 by the coactivator p300 is 
responsible for this reversal of KLF5 function [272-274]. 
The acetylase p300 is a well established co-activator of the 
TGF-β/Smad pathway in epithelial cells [275]. It has been 
recently proposed that FOXO3A also positively regulates 
p15 expression and interacts with both Smad4 and KLF5 on 
the p15 promoter, with this interaction being also dependent 
on the acetylation of KLF5 by p300 [273]. 
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2.3.5. HNF4α  
 Hepatic bile acids are highly cytotoxic and their synthesis 
is tightly controlled. During cholestatic liver injury (BDL), 
hepatic cells release proinflammatory cytokines (IL-1β, 
TNF-α) and growth factors (hepatic growth factor, TGF-β). 
Numerous studies have shown that TGF-β1, TNF-α, and 
insulin inhibit transcription of cholesterol 7a-hydroxylase 
(Cyp7a1) gene and bile acid synthesis in human hepatocytes. 
However, it has been recently reported that Smad3, FOXO1, 
and HNF4α can synergistically stimulate rat Cyp7a1 gene 
transcription forming a complex on the Cyp7a1 promoter, 
while both insulin and TNFα prevent TGF-β activation of 
Cyp7a1 [276].  
2.4. Hepatocytes  
 C/EBPs are a family of six proteins, the most widely 
expressed and most well studied being the C/EBPα and 
C/EBPβ isoforms [277]. These transcription factors control 
the differentiation of a range of cell types, and play key roles 
in regulating cellular proliferation through interaction with 
cell cycle proteins. More recently, C/EBPs have been des-
cribed as both tumor promoters and tumor suppressors. The 
ability of C/EBPα to direct cellular fate in a context-specific 
manner is thought to depend on the presence of specific 
collaborating transcription factors [278]. 
 The specification of hepatocytes during normal develop-
ment occurs in the absence of C/EBPα, but recently it has 
been proposed that C/EBPα can direct hepatoblasts towards 
the hepatocyte lineage in the setting of transplantation. 
C/EBPα-deficient bipotent embryonic hepatoblasts give rise 
almost exclusively to biliary epithelial cells when trans-
planted, whereas wild-type cells develop into hepatocytes 
under these conditions [279]. This notion is supported by the 
observation that C/EBPα null mouse hepatocytes display 
traits normally associated with biliary epithelial cells [280]. 
 C/EBPβ has been known for some time to contribute to 
insulin-regulated gene expression through interaction with an 
IRS in the promoter of the gluconeogenic gene pepck and 
insulin-like growth factor binding protein-1 (Igfbp1), where 
C/EBPβ interacts with FOXO1 [281]. FOXO1 binds pepck 
in a C/EBPα-dependent manner in vivo, while insulin 
inhibits the C/EBPα-dependent transcription of pepck [282]. 
The relevance of this regulation is highlighted in the 
perinatal stage. In prenatal stage nutrients are provided from 
mother via the placenta, but nutritional supplies from mother 
stop abruptly after birth. Thus, newborns have to survive by 
their own metabolic functions immediately after birth; 
C/EBPα is indispensable for the onset of gluconeogenesis in 
perinatal liver [283, 284]. However, C/EBPα is already 
expressed in fetal liver, indicating that additional factors are 
required. Importantly, FOXO1 expression is strongly in-
creased in the perinatal liver and promotes C/EBPα-
dependent transcription of pepck. These results not only 
indicate that FOXO1 regulates gluconeogenesis cooperat-
ively with C/EBPs, but also establish a link between meta-
bolism and FOXO factors in liver development [282, 285].  
Multidrug Resistance 
 Another regulatory circuit likely to be corregulated by 
FOXOs and C/EBPs is multidrug resistance. The develop-
ment of multidrug resistance 1 (MDR1) can be mediated by 
a number of different mechanisms, but basically involves the 
induction of detoxification systems. Elevated gene expres-
sion of MDR1 has often been a major cause of chemo-
resistance in many cancer cells. Investigation of the trans-
criptional control of MDR1 revealed that the proximal 
promoter region of the human MDR1 gene contains a 
FOXO-binding site, which partially overlapped with a 
C/EBPβ binding region. FOXO1 was shown to regulate 
MDR1 expression, but cooperativity with C/EBPβ, although 
likely to occur, has not yet been tested [286]. 
2.5. Decidualization of Endometrial Stromal Cells 
2.5.1. C/EBPß 
 C/EBPß and FOXO1 also cooperate in the transcription 
of the human decidual prolactin (dPRL) promoter in 
differentiating human endometrial stromal (ES) cells [287]. 
During the menstrual cycle, ovarian estradiol and proges-
terone stimulate the ordered growth and differentiation of 
endometrial tissue compartments. In humans, this includes 
decidualization of ES cells [288]. The decidual process 
requires elevated intracellular cAMP levels and sustained 
activation of the PKA pathway [289]. Expression of the 
tissue specific dPRL promoter is a biochemical marker of 
this process [290]. Previous studies have shown that C/EBPβ 
is induced during ES cell differentiation [291] and 
participates in the formation of a nucleoprotein complex that 
binds the proximal dPRL promoter region upon PKA 
activation. Differentiation of human ES cells into decidual 
cells is also associated with the induction of FOXO1, that 
was identified as a cAMP inducible gene in differentiating 
human ES cells, that interacts and cooperates with C/EBPβ. 
The complex binds to a composite FOXO-C/EBPβ response 
unit in the proximal promoter region or dPRL [287]. FOXO1 
has also been shown to regulate the expression of C/EBPα 
[292] and C/EBPβ [137]. 
2.5.2. HoxA 
 C/EBPβ is not the only transcription factor that co-
operates with FOXO in endometrial decidualization. Homeo-
box transcription factors (Hox) contain a highly conserved 
DNA binding domain termed the homeodomain [293]. Hox 
proteins are developmentally regulated transcription factors 
that are important for spatial identity and differentiation of 
tissues in the developing embryo. The Hox factors play 
crucial roles in the modulation of vascular function although 
little is known about their downstream target genes. HoxA5 
is expressed in quiescent endothelial cells but it becomes 
down-regulated upon endothelial cell activation by angio-
genic stimuli. Moreover, increased HoxA5 expression 
blocked angiogenesis in vivo and cell migration in vitro 
[294]. Therefore, both the expression pattern and activity of 
HoxA5 resemble those of FOXO1 [295]. HoxA10 also has a 
similar pattern of expression that FOXO1 during different 
stages of the baboon menstrual cycle and pregnancy [296], 
and HoxA10 null mutant mice exhibit infertility due to 
compromised endometrial decidualization during blastocyst 
implantation [297]. 
 The FOXO1 transcriptional target IGFBP-1 is mainly 
produced by hepatocytes and decidualized endometrium. 
IGFBP-1 inhibits IGF-dependent cellular growth and 
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differentiation both in vitro [298] and in vivo [299, 300] and 
is thought to play a role during blastocyst implantation [295]. 
Transgenic mice overexpressing HoxA5 show impaired 
postnatal growth that correlates with a strong upregulation of 
IGFBP-1 in the liver [301]. HoxA5 upregulation of IGFBP-1 
is probably dependent on its interaction with FOXO1 since 
these factors cooperatively activate the Igfbp1 promoter in a 
fibroblast cell line. However, the same authors proposed that 
Hoxa5 can also repress FOXO1 activity in another cellular 
system. FOXO1 also associates directly with HoxA10 in 
vitro, and this complex also cooperatively transactivates the 
Igfbp1 promoter [296].  
2.5.2. Progesterone Receptor (PR) 
 The postovulatory rise in progesterone levels in pre-
paration for pregnancy induces extensive remodeling of the 
endometrium, associated with morphological and bioche-
mical differentiation of stromal cells into decidual endo-
metrium. As mentioned, differentiation of human ES cells 
into decidual cells is associated with the induction of 
FOXO1 and its transcriptional targets. Knockdown of the 
progesterone receptor (PR) in ES cells disrupts the regulation 
of FOXO1 target genes involved in differentiation (Igfbp1, 
PRL, and WNT4) and cell cycle regulation (CDKN1, CCNB2 
and CDC2) [302]. This suggested a functional link between 
PR and FOXO1 in the endometrium [302]. This idea is 
supported by a recent report demonstrating that many type I 
endometrial cancers in which PTEN is inactivated (ulti-
mately leading to a constitutively activation of AKT and 
inhibition of FOXO1), expression of a constitutively active 
FOXO1 mutant induces cell cycle arrest and apoptosis in a 
PR-dependent manner [303]. This functional link is probably 
dependent on a PR/FOXO1 interaction, as already shown in 
the case of Igfbp1 [304]. Liganded PR is recruited together 
with FOXO1 to the Igfbp1 promoter to induce its expression 
[305]. Similarly, FOXO3A has been shown to interact and 
induce hormone dependent activation of PR-A [306].  
2.6. Adipocytes 
 An essential role for FOXO1 has recently been proposed 
in adipocyte differentiation. Downregulation of FOXO1 
decreases the expression of the adipogenic transcription 
factors PPAR-γ and C/EBPα [292], and FOXO1 has been 
associated with pro-inflammatory gene expression in obese 
subjects. Obesity is associated with a low-grade inflamma-
tion in adipose tissue resulting from increased production of 
pro-inflammatory cytokines and which can subsequently 
contribute to the development of insulin resistance. How-
ever, the mechanisms underlying the transcriptional regula-
tion of pro-inflammatory genes are still unclear. In TNFα-
treated adipocytes, AKT-dependent phosphorylation of 
FOXO1 is reduced, enhancing its transcriptional activity. It 
has been proposed that FOXO1 could increase pro-inflam-
matory gene expression by inducing C/EBPβ through direct 
binding to its promoter [137]. 
 Adiponectin is an adipocyte-derived hormone that plays 
an important role in energy metabolism. It enhances insulin 
sensitivity and improves fatty acid oxidation in skeletal 
muscle. Although adiponectin is predominantly produced by 
adipose tissues, plasma adiponectin concentration and  
 
adiponectin gene expression are inversely correlated with 
adiposity [307]. Adiponectin gene expression is turned on 
during adipocyte differentiation after clonal expansion [308], 
coinciding with the initiation of FOXO1 activity. FOXO1 is 
inhibited during clonal expansion (days 1 and 2), through 
phosphorylation and exclusion from the nucleus. By day 3 of 
differentiation, phosphorylation of FOXO1 is decreased, and 
it is located in the nucleus [64]. FOXO1 has been proposed 
to positively regulate the expression of adiponectin by 
binding to its promoter. This activation involves interaction 
of FOXO1 with C/EBPα, that serves as a FOXO coactivator, 
and this interaction is enhanced by the deacetlylase SirT1 
[309]. 
2.7. Hematopoiesis 
 Given the importance of FOXO/C/EBPs cooperative 
interaction in other systems, it would be interesting to 
investigate whether these factors are functionally linked in 
the control of hematopoiesis and hepatopoyetic stem cells 
(HSCs). The role of FOXO transcription factors in the 
regulation of hematopoiesis has recently been investigated 
using mice harboring the interferon-inducible transgene Mx-
Cre in a FOXO1/3/4LoxP/LoxP background, enabling con-
ditional deletion of FOXO1, 3 and 4 in the adult hemato-
poietic system. FOXO deficient mice exhibit increased levels 
of myeloid cells and aberrant development of the B and T 
lymphoid compartments, including a decrease in peripheral 
blood lymphocytes. The FOXO deficient animals eventually 
develop leukocytosis characterized by a relative neutrophilia 
and lymphopenia. Deletion of FOXO1, 3 and 4 not only 
induced HSC proliferation, but also increased the level of 
apoptosis in HSCs and myeloid progenitors. This might 
explain the reduction of HSC numbers that followed the 
initial expansion, and was reflected in a defective long-term 
repopulating capacity of bone marrow cells [58]. Interest-
ingly, a critical role in regulation of both myelopoiesis and 
self-renewal of HSCs is played by C/EBPα [310]. It was 
recently demonstrated that the inhibitory phosphorylation of 
GSK-3 by AKT results in dephosphorylation and subsequent 
activation of C/EBPα in hematopoietic progenitors. More-
over, active GSK-3 induces eosinophil differentiation and 
inhibits neutrophil development, whereas dephosphorylation 
of C/EBPα induces neutrophil differentiation [311]. There-
fore, inhibition of GSK-3 activity affects lineage develop-
ment, at least in part, through regulation of C/EBPα trans-
criptional activity, suggesting that pharmacological modula-
tion of this signaling module could provide a means of 
clinically modulating bone marrow activity.  
 A recent report has evidenced an unexpected role of 
FOXO3A in Chronic myeloid leukaemia (CML) that is 
closely link to the capacity of FOXO3A to maintain the 
renewal capacity of hematopoietic stem cells. Chronic mye-
loid leukaemia (CML) is caused by a genetic abnormality 
that generates BCR-ABL, a constitutively active tyrosine 
kinase [312]. The tyrosine kinase inhibitor imatinib is a 
breakthrough for CML therapy, however, imatinib does not 
deplete the leukaemia initiating cells (LICs) that drive the 
recurrence of CML [313]. FOXO3A was found to play an 
essential role in the maintenance of CML LICs. The authors 
also showed that in this setting TGFβ activity is fundamental 
to control FOXO3A nuclear localization [314]. 
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3. NUCLEAR HORMONE RECEPTORS: AT THE 
CROSSROADS OF METABOLISM AND CELL 
PROLIFERATION CONTROL 
 Interaction between FOXOs and nuclear hormone 
receptors (NHR) was first detected in C. elegans, where the 
NHR DAF-12, which had been implicated in insulin-like 
signaling, was shown to interact with the forkhead factor 
DAF-16 [315]. FOXO factors have since been shown to 
interact with numerous NHRs (androgen receptor (AR), 
estrogen receptor α (ERα), PR, GR, constitutive androstane 
receptor (CAR), retinoic acid receptor (RAR), pregnane X 
receptor (PXR), PPARγ, thyroid hormone receptor (TR), and 
HNF-4 [77, 78, 316, 317]. It has been suggested that FOXOs 
might interact with nuclear receptors through an LxxLL 
motif located C-terminal of the forkhead DNA-binding 
domain [318]. 
3.1. PPARs 
3.1.1. PPARγ  
 The PPAR family of ligand-activated transcription 
factors includes three isoforms (α, β/δ, γ) that differ in their 
tissue distribution and ligand specificity: PPAR-β/δ are 
ubiquitously expressed in many tissues; PPARα is 
predominantly found in hepatocytes, cardiomyocytes and 
enterocytes, where it regulates lipid catabolism; and PPARγ 
is mainly expressed in insulin-responsive tissues, where it 
plays a pivotal role in adipocyte differentiation and the 
expression of adipose-specific genes [319]. It was originally 
reported that FOXO1 prevents the differentiation of preadip-
ocytes [63] and negatively regulates PPARγ expression in 
primary adipocytes [320], although this effect did not seem 
to involve the direct binding of FOXO1 to the promoter, 
since a DNA-binding mutant was competent in this regula-
tion. The transcription factor responsible for the direct DNA 
binding activity is still unknown. However, a later report 
suggested that FOXO could positively regulate adipocyte 
differentiation, since knockdown of FOXO1 downregulates 
key adipogenic transcription factors such as C/EBPα and 
PPARγ [292]. 
 In contrast to the previously discussed FOXO/C/EBPβ 
cooperativity, FOXO1 interaction with PPARγ results in a 
negative regulation of its transcriptional activity by 
preventing PPARγ/RXR interaction with DNA. Through its 
binding to PPARγ, FOXO1 is recruited to PPAR response 
elements (PPRE) on PPARγ target genes, where it interferes 
with promoter occupancy of the receptor. The FOXO1 
transrepressional function, which is independent of the 
transactivation effects, does not require a functional FOXO1 
DNA binding domain, but does require an evolutionally 
conserved 31 amino-acid domain containing the LXXLL 
motif [318]. SirT2 deacetylation of FOXO1 has been shown 
to result in its increased repressive interaction with PPARγ, 
which has been proposed to mediate Sirt2 dependent 
suppression of adipocyte differentiation [321]. Conversely, it 
has also been proposed that PPARγ can inactivate FOXO1 
[315]. 
 An antagonistic action of FOXO1 on PPARγ activity is 
further supported by functional correlations such as the 
observation that FOXO1 down-regulation, like PPARγ 
activation, improves peripheral insulin sensitivity in diabetic 
mice [322]. FOXO1-induced increases in insulin resistance 
are normally attributed to its gluconeogenic activity. Other 
more recent reports show that FOXO1 haploinsufficiency 
protects mice against obesity-related insulin resistance and 
results in increased PPARγ levels and activity [323]. This 
effect is attributed to the fact that FOXO works as a negative 
regulator of PPARγ activity [318]. Furthermore, adipocytes 
from insulin resistant mice show reduced phosphorylation 
and increased nuclear accumulation of FOXO1, coupled to 
lowered expression of endogenous PPARγ target genes. 
Thus, it seems that the innate FOXO1 transrepression 
function enables insulin to augment PPARγ activity, which 
in turn leads to insulin sensitization, and this feed-forward 
cycle represents positive reinforcing connections between 
insulin and PPARγ signaling. 
GLUT4: a Case Study in FOXO-Mediated Transrepression 
of PPARγ 
 Glucose uptake in eukaryotic cells is mediated by the 
GLUT family of glucose transport proteins. GLUT4 is 
referred to as ‘the insulin-responsive isoform’ because it is 
mainly expressed in insulin-responsive tissues, where it 
mediates glucose uptake in response to acute insulin 
stimulation [324]. PPARγ, in its unliganded form, binds to 
cis-elements on the GLUT4 promoter, keeping it in a 
repressed state. Binding of the ligand thiazolidinedione to 
PPARγ detaches PPARγ from the GLUT4 promoter, result-
ing in increased GLUT4 expression and, subsequently, en-
hanced insulin responsiveness [325]. In 2002 it was shown 
that the oncogenic fusion protein Pax3/FOXO1 activates 
GLUT4 gene expression both in vivo and in vitro [326]. In 
fact, FOXO1 can either repress or activate transcription of 
the GLUT4 gene, depending on the cell context. The pro-
posed model is that FOXO1, following insulin stimulation, is 
excluded from the nucleus, which is followed by a partial 
derepression of PPARγ activity on the GLUT4 promoter. 
3.1.2. PPARα  
3.1.2.1. Myocytes 
 Accumulated evidence suggests that FOXO1 works as a 
coactivator of PPARα in myocytes. FOXO1 was initially 
found to enhance the expression of lipoprotein lipase (LPL), 
a PPARα target gene [327]. LPL regulates lipid usage in 
muscle cells by hydrolyzing plasma triglycerides to fatty 
acids, and is upregulated during fasting. It was observed that 
FOXO1-induced LPL levels increased even further in the 
presence of PPARα ligand, suggesting a cooperative interac-
tion between PPARα and FOXO1. This idea is supported by 
functional correlations; for example FOXO1 activation in 
muscle cells increases CD36 (a PPARα target gene) in 
plasma membrane and sarcolema, and increases fatty acid 
uptake and oxidation [328-330]. However, it was later 
proposed that PPARα can inhibit FOXO1 transcriptional 
activity by decreasing its DNA binding capacity [331]. 
3.1.2.2. Hepatocytes 
 Hypertriglyceridemia is characterized by increased pro-
duction of very-low-density lipoprotein (VLDL) and/or 
decreased clearance of triglyceride (TG)-rich particles. An 
important factor in plasma VLDL-TG metabolism is 
apolipoprotein C-III (apoC-III). ApoC-III is a VLDL that it 
is thought to inhibit hepatic uptake of TG-rich particles. It 
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functions as an inhibitor of lipoprotein lipase and hepatic 
lipase, and plays a pivotal role in the hydrolysis and clear-
ance of TG-rich particles such as VLDL-TG and chylo-
microns. Elevated plasma apoC-III levels are associated with 
impaired clearance of TG-rich particles, leading to the 
accumulation of TG-rich lipoprotein remnants in plasma and 
the development of hypertriglyceridemia [332]. FOXO1 sti-
mulates hepatic apoC-III expression, which is counteracted 
by insulin [333]. PPARα has been shown to interact with 
and antagonize FOXO1-induced hepatic upregulation of 
apoC-III expression [331]. 
 The pseudokinase tribble 3 (Trb3) has been proposed to 
regulate insulin sensitivity via AKT inhibition [334]. Fasting 
and diabetes promote Trb3 expression through PGC-1α 
coactivation of PPARα on the Trb3 promoter [335]. As we 
have already seen, PGC-1α is also a FOXO1 coactivator, 
and FOXO1 might therefore have been predicted to increase 
Trb3 expression. However, FOXO1 inhibits Trb3 expression 
while insulin induces it, and it has been proposed that part of 
FOXO1 activity on Trb3 may be mediated by its trans-
repression of PPARα, although the cis-acting elements in the 
Trb3 promoter required for FOXO1 repression are distinct 
from those utilized by PGC-1α/PPARα [65]. 
3.1.3. PPARδ  
 There is evidence of significant redundancy in the 
regulatory effects of PPARα and PPARδ. PPARδ is the 
major PPAR isoform in muscle, and is thus likely to be more 
important in muscle bioenergetics. An important PPARα/δ 
target gene, PDK4 [336], is almost unaltered in PPARα null 
mice [337], but its expression is almost blunted in PPARδ 
knockous [338]. As already noted, PDK4 is also a FOXO1 
target gene [120]. Activation of PPARδ in muscle induces a 
fasting-like phenotype characterized by increased fatty acid 
oxidation and suppressed glucose oxidation [339]. This is 
similar to the phenotype induced by FOXO1, suggesting that 
some PPARδ effects in muscle might be mediated via 
FOXO1. In fact, PPARδ has been suggested to induce 
FOXO1 gene expression through direct binding to its 
promoter [340]. The notion that FOXO/PPAR complexes 
may regulate fatty acid use is further supported by the 
findings that both factors induce muscle fiber type switch 
[228, 341], and that both have been reported to initiate a 
muscle atrophy program [125, 342]. 
3.2. The Liver X Receptors (LXR) 
 Liver X Receptors (LXR) α and β are central regulators of 
cholesterol metabolism in mammals [343]. LXR activation 
in rodent liver upregulates Cyp7a1, a member of the 
cytochrome P450 family that is crucial for bile acid synthesis 
[344]. In the intestine, LXR controls the reabsorption of 
cholesterol via the expression of ABCG5 and ABCG8 [345]. 
Pharmacologic activation of these receptors in vivo results in 
increased high-density lipoproteins (HDL) levels, net whole 
body cholesterol loss, and reduced atherosclerosis [346]. 
Sterol regulatory element binding protein 1c (SREBP1c) is a 
master regulator of lipogenic gene expression in liver and 
adipose tissue, where its expression is regulated by a 
heterodimer of retinoid X receptor (RXR) and LXR. 
Expression of FOXO1 negatively correlates with that of 
SREBP1c in skeletal muscle during nutritional change, and it 
has been described that FOXO1 suppresses RXR/LXR-
mediated SREBP1c promoter activity in vitro and in vivo. 
These findings provide in vitro evidence that RXR/LXR up-
regulates SREBP1c gene expression and that FOXO1 
antagonizes this effect of RXR/LXR in skeletal muscle 
[347], suggesting a FOXO1/LXR interaction, but this has not 
been confirmed. 
3.3. PXR and CAR 
 PXR and CAR were originally identified as xenosensors 
that regulate the expression of Phase I and Phase II drug-
metabolizing enzymes and transporters. Recent results 
suggest that PXR and CAR also have important endobiotic 
roles in energy metabolism by affecting the metabolism of 
fatty acids, lipids and glucose [348, 349]. Expression of the 
major gluconeogenic enzymes pepck and g6pase is dra-
matically suppressed in PXR transgenic mice [350]. 
Consistently, activation of PXR cancels cAMP/ CREB 
dependent induction of g6pase and this effect was found to 
be mediated by PXR direct interaction with CREB [351]. 
Further investigation showed that activated PXR and CAR 
act as corepressors of FOXO1, thus identifying another posi-
tive regulator of gluconeogenesis, resulting in the suppres-
sion of FOXO1-mediated activation of gluconeogenic gene 
expression [352]. These results further support the notion 
that interplay between the CREB and FOXO1 pathways is 
important in the control of gluconeogenesis [163], mediated 
at least in part by FOXO1 itself, acting as a negative 
regulator of the CREB pathway. The biological effect of the 
FOXO1–PXR complex seems to be gene specific, since 
FOXO1 can also act as a co-activator in PXR and CAR 
mediated xenobiotic responses [352]. Positive cooperation 
among FOXO1, HNF-4, PGC-1α and PRX/CAR has also 
been reported in the regulation of ALAS1, a key regulator of 
heme synthesis, and hence the response to toxic agents that 
require P450 protein-dependent detoxification [353]. 
3.4. Steroid Receptors 
 Steroid hormone receptors such as AR, ER, and GR are 
ligand-dependent transcription factors that belong to the 
nuclear receptor superfamily [354]. Steroid receptors have 
been implicated in the development of several types of 
cancer such as prostate cancer, breast cancer and ovarian 
cancer. FOXO transcription factors play a significant role in 
the prevention of tumorigenesis [355, 356]. Association of 
FOXOs with steroid receptors can either inhibit or enhance 
their transcriptional activity and these interactions could play 
a role in the development of steroid-dependent cancers. 
3.4.1. AR 
 AR is responsible for male sexual differentiation and 
male pubertal changes. AR signaling is also necessary for the 
development and maintenance of prostate cancer, and 
antagonists are currently used for therapy [357], although the 
molecular mechanisms are poorly understood. It was initially 
observed that loss of PTEN was an important event during 
human prostatic tumorigenesis. PTEN is a tumor suppressor 
and a negative regulator of the PI3K/AKT pathway. It was 
subsequently noted that inhibition of PI3K drastically 
reduced the transcriptional activity of AR, resulting in 
decreased androgen-induced proliferation [358, 359]. Further 
investigation demonstrated that expression of FOXO1 in 
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prostate cancer cells is lower than in healthy prostate tissue, 
and forced expression of FOXO1 suppressed AR-dependent 
gene expression in a manner independent of the FOXO1 
transcriptional activating function, suggesting that FOXO1 
may inhibit AR activity [360]. In fact FOXO1 interacts 
directly with the C terminus of AR in a ligand-dependent 
manner and disrupts ligand-induced AR subnuclear compart-
mentalization. Similar to other steroid receptors, the AR is 
composed of an N-terminal domain (NTD) containing a 
major activation function, a DNA-binding domain, a hinge 
region, and a C-terminal ligand-binding domain (LBD), 
which contains a weak activation function. Androgens 
induce an interaction between the N- and C-terminal regions, 
an event that is critical for the biological actions of the 
receptor [361, 362], and it is this interaction that is disrupted 
by FOXO1. FOXO1 also cancels the binding of p160 steroid 
receptor co-activator (SRC) to the AR NTD. Moreover, the 
AR N/C interaction is inhibited by PTEN, which also 
inhibits AIB1 (a member of the SCR-1 family) recruitment 
to AR NTD [363]. FOXO1 inhibition of the AR has recently 
been found to be partially dependent on its interaction with 
the histone deacetylase HDAC3. In vitro, FOXO1 reduces 
the promoter activity of the AR target gene prostate specific 
antigen (PSA) [316, 364]. Furthermore, the AR has also been 
reported to repress the expression of both FOXO1 and 
FOXO3A, which is also normally expressed in prostate 
tissue [316]. 
 Evidence that FOXO3A is also a negative regulator of 
the AR comes from the identification of a FOXO3A binding 
site in the promoter of the antiapoptotic FAD D-like 
interleukin-1β-converting enzyme (FLICE)-like inhibitory 
protein (FLIP). Treatment with androgens in the absence of 
PI3K/AKT signaling increases FLIP expression, while it is 
downregulated by expression of either PTEN or FOXO3A. 
A FOXO3A binding site was identified in the FLIP promoter 
and was shown to be necessary for the combined effects of 
androgens and FOXO3A on FLIP transcription. FOXO3A 
was also shown to interact with AR, suggesting that 
FOXO3A, like FOXO1, can work as a negative modulator of 
AR activity [365].  
 Beyond prostate cancer, it has been noted that some other 
physiological actions of the growth hormone (GH)-IGF-1 
system and androgens are very similar and overlap. For 
example, many studies have shown that both hormones act to 
stimulate muscle strength, increase bone mineral density, 
and decrease abdominal fat accumulation [366].  
3.4.2. ER 
 Another steroid receptor implicated in the proliferation of 
prostate cancer cells is ERβ. ERα and ERβ interaction with 
FOXO1 has been described. ER is mainly expressed in ma-
mmary gland tissue, ovaries and uterus. Binding of estrogen 
leads to homodimerization and transcription of estrogen-
responsive genes, which stimulate cell proliferation, inva-
sion, metastasis and angiogenesis while inhibiting apoptosis 
[367]. Breast cancer is the most common cancer diagnosed 
in women worldwide, and is the second leading cause of 
cancer death. Approximately 70% of human breast cancers 
express ERα, and it is frequently overexpressed in breast 
cancer cells. Moreover, the cumulative exposure of breast 
epithelium to estrogen has been associated with the 
development of breast cancer. Many ERα-positive tumor 
cells undergo apoptotic cell death when they are deprived of 
estrogen, and ablation of the ERα gene delays the onset of 
tumor development in mouse models, indicating that ER-
mediated signaling plays an important role in breast cancer 
[368]. Apart from ER-mediated effect of estrogen, mem-
brane initiated actions are diverse, including activation of 
PI3K/AKT. Importantly, constitutive activation of the 
PI3K/AKT signally pathway has also been associated with 
development of breast cancer and overexpression of PI3K is 
sufficient to confer a malignant phenotype. Activation of the 
PI3K pathway serves to repress FOXOs-mediated growth 
arrest and apoptosis [369]. One study has shown that 
upregulation of FOXO3A in breast cancer cells enhances 
expression of the proapoptotic (and FOXO target) Bim and 
induces apoptosis [370]. Another study showed that the 
estradiol-induced increased survival of breast cancer cells 
depends on inactivation of FOXO1 [371]. 
 FOXO1 interacts with ERα in a ligand-dependent man-
ner. However, there are conflicting reports as to the effect of 
this interaction on ER transcriptional activity. It has been 
reported that FOXO1 can both activate [317] and repress 
[77] ERα. Importantly, the cell cycle arrest induced by 
FOXO1 in mammary cancer cells is abrogated by estradiol 
[77]. More recently, FOXO3A was found to interact with 
both ERα and ERβ and to inhibit their transcriptional 
activities. Gene expression profiling by DNA microarray 
suggested that FOXO3A has a global inhibitory effect on the 
expression of ER target genes. This report also demonstrated 
that FOXO3A suppresses proliferation of breast cancer cells 
by inducing the expression of key CDK inhibitors and 
reducing the expression of cyclin D1. Moreover, FOXO3A 
suppresses estradiol-induced tumorigenesis in an animal 
model of breast cancer, suggesting that FOXO3A interaction 
with ERs is critical for its tumor-suppression activity in 
estrogen-dependent breast tumors [372]. 
3.4.2. TR and RAR 
TR and RAR. FOXO1 has been proposed to interact and 
stimulate both RAR and TR mediated transactivation in a 
ligand-independent manner [77]. 
4. OTHER TRANSCRIPTION FACTORS  
4.1. p53 
 The transcription factors p53 and FOXO are both 
activated in response to stresses that lead to events such as 
cell survival or apoptosis. Several studies show striking 
similarities between p53 and FOXO [373], such as post-
translational modifications, common signaling pathways, 
common target genes, similar stress responses, and similar 
mutual interactions with various proteins. For example, both 
are associated with cell cycle arrest, apoptosis, tumor 
suppression and aging [374], and they share several target 
genes like those involved in the regulation of metabolism 
and apoptosis. Recently it has been shown that FOXO3A can 
activate transcription via p53 sites. FOXO3A and p53 
interact directly and cooperatively to regulate tumor 
suppression and metabolic control in a nutritional status 
sensitive manner [375, 376]. It has been further noted that 
FOXO3A decreases the DNA binding activity of p53 and 
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promotes its cytoplasmic translocation [375], where is 
directed to the mitochondria and suppresses the antiapoptotic 
function of Bcl-2 and Bcl-xL [377]. The structure of the 
FOXO3A/p53 complex has been elucidated revealing that 
p53 destabilizes an intramolecular interaction between the 
forkhead domain and the CR3 activation domain, while 
interacting with both domains simultaneously [23]. A recent 
report proposes that FOXO3A and p53 can have opposing 
actions in relation to apoptosis. Oxidative stress induces 
interaction of FOXO3A and p53, and results in the inhibition 
of FOXO3A trasncriptional activity while p53 activity is 
unaffected in COS-7 cells. p53 prevents FOXO3A induction 
of the pro-apoptotic Bim and Bcl6, but expression of p27 and 
cyclinG2 is not [378]. 
4.2. c-myc 
 Proapoptotic Arf/p53 signaling is the main Myc-induced 
tumor-suppressing pathway [379]. Additionally, Myc 
cooperates with constitutive AKT signaling to accelerate B-
cell lymphomagenesis [380]. AKT-mediated phosphory-
lation of FOXO proteins is the critical PI3K signaling 
component that substitutes for oncogenic Ras in Myc-
induced proliferation and focus formation in vitro [381, 382]. 
The tumor-suppressive potential of FOXO factors during 
Myc-driven lymphomagenesis is mediated through the 
induction of Arf. FOXO proteins bind to a specific site 
within the Ink4a/Arf locus and activate Arf expression. 
Moreover, expression of the p53 upstream regulator p19Arf 
is virtually undetectable in most FOXO negative Myc-driven 
lymphomas. These data, while providing further evidence for 
a close link between the FOXO and p53 tumor suppressor 
pathways, also indicate that the observed collaboration 
between p53 and FOXO is also consistent with the action of 
an unidentified FOXO target upstream of p53 [383]. 
 Microarray analysis of a diverse group of human cancers 
has shown almost mirror image expression patterns for 
FOXO factors and Myc, supporting the notion of a negative 
cross-talk between the two signaling pathways. Recently, a 
direct interaction between Myc and FOXO3A has been 
demonstrated. FOXO1, FOXO3A, and FOXO4 have been 
found to transactivate p27 and to control cell cycle 
progression and apoptosis in various cell types [40, 42]. 
Activation of WEHI 231 B lymphoma cells with anti-IgM 
induces FOXO3A and hence increases p27 levels [384]. On 
the other hand, ectopic expression of Myc reduces the 
induction of p27 associated with anti-IgM treatment [385]. 
Recent evidence shows that activation of p27 by FOXO3A is 
repressed by Myc, and that Myc directly inhibits FOXO3A-
mediated activation of p27 promoter [386]. 
4.3. STAT3 
 The signal transducer and activator of transcription 3 
(STAT3) participates in various critical cellular processes 
[387], including the differentiation of neural stem cells into 
astrocytes [388]. In addition, STAT3 supports the renewal 
capacity of neural stem cells [389]. These activities have 
been connected to the observation that deregulation of 
STAT3 signaling can contribute to glial cell transformation 
[390]. STAT3 has in fact been assigned a pro-oncogenic 
function in a subset of glioblastomas [391] and in several 
cell types outside the nervous system [392]. It has been 
shown that STAT3 activation promotes the survival of 
certain glioblastoma cell lines in vitro [393]. That STAT3 
has also a tumor-suppressive function, intimately linked to 
PTEN function, was evidenced in knockout studies. PTEN 
deficiency, and consequent AKT activation, tightly corre-
lates with inactivation of the LIFRβ–STAT3 signaling path-
way in astrocytes. The cytokine receptor LIFRβ has been 
identified as a direct target of FOXO3A in human glio-
blastomas, providing an explanation of how the PTEN–
AKT–FOXO cascade modulates both glial developmental 
and the LIFRβ–STAT3 signaling pathway. The intersection 
of these two signaling networks allows the loss of PTEN to 
down-regulate LIFRβ expression and inhibit STAT3 activity, 
thereby relieving STAT3’s suppression of glial cell 
proliferation, invasiveness, and transformation. Strikingly, in 
contrast to STAT3’s tumor-suppressive function in the 
PTEN pathway, STAT3 in its pro-oncogenic mode 
associates with the oncoprotein epidermal growth factor 
receptor type III variant (EGFRvIII) in the nucleus thereby 
inducing glial transformation [390].  
 Direct inhibitory interaction between FOXO3A and 
STAT3 has recently been demonstrated in the context of the 
leptin signaling pathway. Leptin is a hormone secreted by 
adipose tissue that regulates food intake and energy 
expenditure. Leptin levels are often higher in obese subjects. 
However, in these subjects leptin fails to be effective 
because its signaling pathway is impaired, a phenomenon 
known as leptin resistance. Leptin actions are mediated by 
binding and activation of the long form leptin receptor 
(OBRb) [394]. Activated OBRb turns on the JAK2-STAT3 
pathway, inducing STAT3 phosphorylation and translocation 
into the nucleus, where it regulates its target genes such as 
the neuropeptide pro-opiomelanocortin (POMC) [395, 396]. 
A recent study has shown that STAT3 activates POMC 
promoter in response to leptin through a mechanism that 
requires an specificity protein 1 (SP1)-binding site. FOXO1 
binds to STAT3 and prevents the formation of a STAT3/SP1 
on the POMC. FOXO3A inhibition of STAT3-mediated 
leptin action thus suggests a potential mechanism of leptin 
resistance [210].  
 The negative interplay between the STAT3 and FOXO 
pathways is also implicated in the regulation of liver 
gluconeogenesis, where STAT3 suppresses the expression of 
gluconeogenic genes [397]. The deacetylase SirT1, which as 
we have seen induces gluconeogenesis in response to fasting 
at least in part through activation of FOXO1 and PGC-1α, 
has recently been shown to deacetylate and inactivate 
STAT3, hence suppressing its inhibitory action on 
gluconeogenesis [398]. 
4.4. RUNX 
 RUNX transcription factors are α subunits of the 
polyomavirus enhancer-binding protein 2 (PEBP2)2/core-
binding factor (CBF), which consists of α and β subunits. 
Three RUNX transcription factors, RUNX1, RUNX2, and 
RUNX3, have been identified in mammals. RUNX1 is 
essential for definitive hematopoiesis, RUNX2 plays critical 
roles in osteoblast maturation and osteogenesis, and RUNX3 
is ubiquitously expressed and involved in a variety of 
biological activities including the development of the 
gastrointestinal tract, neurogenesis, and lineage specification 
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of thymocytes. RUNX3 is an important downstream effector 
of TGFβ signaling in gastric epithelium. It activates Smads 
through direct interaction [399]. RUNX3-deficient mice 
exhibit hyperplasias in gastric mucosa due to reduced 
apoptosis and increased proliferation of gastric epithelial 
cells. RUNX3-deficient gastric epithelial cells are less 
sensitive to the proapoptotic and growth inhibitory effects of 
TGFβ [400]. Investigation of RUNX3’s tumor suppressor 
activity revealed that RUNX3 interacts with FOXO3A in 
gastric cancer cell lines, leading to activation of Bim and 
subsequent induction of apoptosis. The same interaction is 
also observed in mouse embryonic fibroblasts, suggesting 
that RUNX3 is involved in apoptosis mediated by Bim, 
which is transcriptionally regulated by FOXO3A in a variety 
of cell types [401]. In this regard is notable that TGFβ 
induces the expression of Bim through a Smad-dependent 
mechanism [402].  
 Another recent report linking TGFβ to RUNX and 
FOXOs, showed that TGFβ specifically induces the expres-
sion of RUNX1 in two hepatocyte cell lines that undergo 
apoptosis upon TGFβ treatment. RUNX1 regulates Bim via 
its direct interaction with FOXO3A on the identified IRS 
promoter element. Consistently, knockdown of RUNX1 or 
FOXO3A decreased TGFβ-induced Bim expression [403]. 
Since Smads and FOXOs are known to cooperate in the 
induction of cell cycle arrest genes, it could be that a Smad/ 
FOXO/RUNX complex is formed on the Bim promoter to 
induce apoptosis. 
4.5. NF-κB 
 NF-κB and c-Jun are known as the two major trans-
cription factors mediating TNF receptor (TNFR) signaling 
[404]. TNF is a potent cytokine that has pleiotropic functions 
in inflammation, cell proliferation, and apoptosis [405]. In 
the TNFR cascade, NF-κB plays a dominant role mediating 
the inflammatory response while blocking apoptosis via 
inhibition of the c-Jun-N-terminal kinase (JNK) [406]. 
Microarray analysis of FOXO3A upregulated genes in 
endothelial cells identified several genes of the TNF signal-
ing pathway, including TNF-α, TANK (TRAF-associated 
NF-κB activator), TTRAP (TRAF and TNF receptor-
associated protein), and κB-Ras1 (IκB-interacting Ras-like 
protein-1), which might be responsible for the activation of 
JNK and suppression of NF-κB, suggesting a link between 
FOXO3A and the TNF receptor signaling [407]. A more 
recent report has showed a direct inhibitory interaction 
between FOXO4 and NFκB. FOXO4 transcriptional activity 
is transiently repressed in colitis induced by trinitrobenzene 
sulfonic acid (TNBS), consistent with a role of FOXO4 in 
intestinal mucosal immunity and inflammatory bowel 
disease (IBD). FOXO4-null mice are more susceptible to 
TNBS injury and show increased transcriptional activity of 
NF-κB in vivo, suggesting that FOXO4 suppresses the 
inflammatory response to TNBS through the inhibition of 
NF-κB transcriptional activity. This report further showed 
that FOXO4 inhibits the in vitro activity of NF-κB on 
several target genes through direct interaction [408]. 
4.6. Four and a Half LIM 2 (FHL2) 
 Four and a Half LIM 2 (FHL2) is differentially expressed 
in normal human myoblasts and their malignant counterparts 
[409]. FHL2 has been proposed to control the hypertrophic 
response to stress in cardiomyocytes [410] and to interact 
with FOXO1 both in vitro and in prostate cancer cells. 
Binding by FHL2 inhibits the transcriptional activity of 
FOXO1 and facilitates its deacetylation by SirT1. These 
findings raise the interesting possibility that interaction of 
FHL2 with FOXO1 and SirT1 might promote prostate 
tumorigenesis in response to increased stress during aging 
[174]. 
4.7. Hipoxia Induced Factor 1α  (HIF-1α) 
 The transcription factor HIF-1 directs the induction of 
glycolysis genes in response to hypoxia. HIF-1 has two 
subunits, α and β. HIF-1α is a labile protein that is stabilized 
under hypoxic conditions [411-413]. Cells that lack PTEN 
(particularly prostate tumors and glyoblastomas) have 
increased HIF-1 activity. FOXO3A is a direct inhibitor of 
HIF-1α and prevents its activation by p300 on the glut-1 
promoter, a HIF-1 target gene. Since HIF is linked to tumor 
angiogenesis via VEGF induction, it has been suggested that 
FOXO may inhibit tumor vasculogenesis at least in part 
through the inhibition of HIF-1 [414].  
4.8. ΔEF1 
 Mature lymphocytes are maintained in the quiescent state 
until recognition of antigen (Ag). Several observations sug-
gest that FOXO transcription factors help to maintain 
lymphocyte quiescence while activation of PI3K is required 
for lymphocyte cell cycle entry [415, 416]. FOXO1 and 
FOXO3A are expressed in resting T and B cells, and are 
rapidly phosphorylated and deactivated upon Ag-receptor 
activation in a PI3K-dependent manner [417, 418]. Activa-
tion of mouse B cells is accompanied by PI3K-dependent 
down-regulation of Ccng2 (encoding the protein cyclin G2) 
and Rbl2 (encoding the retinoblastoma-like protein 
p130/Rb2) [419], both of which are FOXO target genes 
previously implicated in FOXO-dependent quiescence in 
fibroblasts [420, 421]. The promoter sequences of Ccng2 and 
Rbl2 contain several binding sites for the transcription factor 
ΔEF1, a member of the ZEB family of zinc finger factors 
[422]. ΔEF1 can be either a repressor or an activator of trans-
cription in different systems [423]. This protein is involved 
in T cell development and represses IL-2 transcription in T 
cells [424, 425], but its function in B cells had not been 
investigated. It was found that ΔEF1 binds to Ccng2 and 
Rbl2 promoters and activates their expression, synergizing 
strongly with FOXO dependent activation. This cooperation 
does not require direct FOXO DNA-binding and enhances 
cell cycle arrest in B lymphoma cells, thus establishing a 
novel functional cooperation in B cells between FOXO 
transcription factors and ΔEF1 [419]. 
5. NON-TRANSCRIPTION FACTOR FOXO INTER-
ACTING PROTEINS 
5.1. TRIB2 
 TRIB2, a human ortholog of the Drosophila gene 
tribbles, known to regulate furrow formation [426], has been 
recently found to be highly expressed in human melanomas 
where it drives nuclear exclusion of FOXO3A [427]. 
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Although the mechanism involved remains to be elucidated, 
this regulation could play an important role in the main-
tenance of the malignant phenotype of melanoma cells. 
5.2. Follicle Stimulating Hormone Receptor (FSHR) 
 Follicle stimulating hormone (FSH) is required for 
fertility in females, where it binds to FSHR on granulosa 
cells in the ovary. In males, FSHR is present on Sertoli cells 
in the testes, where FSH is necessary for high quality sperm 
production and normal testicular volume. FSH stimulates the 
PI3K/AKT pathway [428] and forms a membrane-bound 
complex that appears to include AKT2 [429], and FOXO1 
[430]. This observation may be related to previous data 
showing that FSH induces HIF in a PI3K/AKT dependent 
manner [431]. 
5.3. Pin1 
 Pin1 is a peptidyl-prolyl isomerase that specifically re-
cognizes phosphorylated serines and threonines flanked by a 
COOH-terminal proline residue [432]. Pin1-mediated iso-
merization modulates the activity of its substrates by 
inducing conformational changes in the peptide backbone. It 
is involved in numerous processes, including the regulation 
of cell proliferation and death. Moreover, Pin1 is over-exp-
ressed in many human cancers and is linked to tumorigenesis 
[433]. In response to cellular stress, FOXOs are phos-
phorylated and recognized by Pin1. Pin1 negatively regulates 
FOXO monoubiquitination at the level of deubiquitination 
through HAUSP/USP7 (Herpes virus Associated USP). This 
inhibits nuclear FOXO translocation in response to hydrogen 
peroxide–induced stress and ultimately leads to decreased 
transcription and expression of FOXO4 transcriptional 
targets, including p27kip1. Notably, an inverse correlation 
between low p27kip1 levels and Pin1 expression was found 
in a panel of primary human breast cancers [434]. 
5.4. Poly(ADP-Ribose)Polymerase-1 (PARP-1) 
 PARP-1 is an abundant and ubiquitous nuclear enzyme 
that catalyzes the nicotinamide adenine dinucleotide (NAD)-
dependent addition of ADP-ribose polymers on a variety of 
target proteins [435]. PARP-1 has been implicated in diverse 
biological processes, including transcriptional regulation, 
chromatin remodeling, DNA repair, cell proliferation, and 
apoptosis [436, 437]. These roles include actions of PARP-1 
as a transcriptional coregulator (either a coactivator or a 
corepressor) of a variety of transcription factors. In some 
cases, enzymatic activity of PARP-1 is required for this 
coregulatory function [438], while in others it is not (for 
example, NF-κB, B-Myb, and RAR) [439]. PARP-1 can 
function as a negative regulator of FOXO1, preventing 
FOXO1-mediated induction of the cell cycle inhibitor 
p27Kip1. Knockdown of PARP-1 decreases cell prolifera-
tion in a manner dependent on FOXO1 function. PARP-1 is 
recruited to the p27Kip1 gene promoter through binding to 
FOXO1, where it poly(ADP-ribosyl)ates the FOXO1 
protein. However, the enzymatic activity of PARP-1 is not 
required for its repression of FOXO1 function. These results 
suggest that PARP-1 acts as a corepressor for FOXO1, 
which could play an important role in the regulation of cell 
proliferation by modulating p27Kip1 gene expression [440]. 
CONCLUDING REMARKS 
 The FOXO transcription factors orchestrate their main 
biological functions trough a complex network of inter-
actions with different transcription factors and cofactors. 
They show remarkable flexibility in their modes of action, 
they can rely or not on specific binding sites on the target 
promoters, the may work as activators or repressors, and 
they can engage in multiple simultaneous complex inter-
action, each one of them responding to a specific signaling 
specificity. Beyond their crucially relevant biological 
functions they are teaching us how molecular networks are 
orchestrated, and it seems that there is much more to come in 
the near future.  
 Although there are not yet any clinical trials that target 
FOXO factors, its crucial role as tumor suppressor and 
regulator of cell metabolism make the FOXO factors 
potentially useful as pharmacological targets. We believe, 
that given the multitude of biological functions regulated by 
FOXOs it is likely that pharmacological modulation of 
specific interactions like those that mediate FOXO regu-
lation by sirtuins and CBP/p300 would provide the necessary 
target specificity that will make modulation of FOXOs 
activity clinically relevant [427]. 
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